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ABSTRACT
Brain dopaminergic pathways are involved in the regulation of motor functions as well as 
processing of reward information. Glial cell line-derived neurotrophic factor (GDNF) has been 
shown to be a potent neurotrophic factor for the brain dopaminergic systems. Biological actions 
of GDNF are mediated by a receptor complex composed of the GDNF family receptor alpha 
(GFRα) 1 and signalling tyrosine kinase receptor RET. GDNF is an important candidate for drug 
targeting in Parkinson’s disease, as it has been shown to protect and promote recovery of brain 
dopaminergic neurons. Almost all drugs of abuse increase dopamine release in mesolimbic and 
nigrostriatal dopaminergic pathways, and the dopaminergic systems are involved in the formation 
of associations between contextual stimuli and rewarding or aversive events. As brain dopaminergic 
pathways are important for perceiving drug reward, and as they undergo plastic changes during 
chronic drug use, interactions between GDNF and responses to abused drugs are of interest. 
This study investigated the role of endogenous GDNF in the regulation of nigrostriatal and 
mesolimbic dopaminergic neurotransmission. The effects of acutely and repeatedly administered 
cocaine and morphine on striatal dopamine release, on behavioural sensitization and on drug 
reward were studied in heterozygous GDNF knockout mice. n addition, this study explored the 
effects of constitutive RET tyrosine kinase receptor activity on brain dopaminergic systems and 
on the locomotor enhancing effects of cocaine in mice. 
Unexpectedly, it was found that extracellular dopamine concentrations were increased in 
striatal brain areas in heterozygous GDNF knockout mice. This was further supported by a 
clear increase in the number of FosB/∆FosB positive nuclei in the caudate/putamen and nucleus 
accumbens in these mice. Thus, the present results indicate that dopaminergic transmission 
is increased in mice with reduced GDNF levels. n addition, heterozygous GDNF+/- mice 
were more sensitive to morphine’s dopamine releasing effect, and reduced GDNF levels 
were associated with a shift in the bell-shaped dose-response curve of morphine to the left. 
nterestingly, it was found that after repeated morphine and cocaine treatment, the extracellular 
dopamine concentrations in the GDNF+/- mice were decreased to a level similar to their wild-
type littermates. n addition, it was found that reduced GDNF levels are involved in a more 
rapid development of tolerance to locomotor enhancing effects of daily 30 mg/kg morphine 
injections, and in increased sensitivity to locomotor sensitization by a 5 mg/kg morphine 
challenge dose. Furthermore, the present results show that constitutive RET activity, caused 
by a single point mutation Met919Thr, robustly increased dopamine concentrations in the 
brain, whereas noradrenaline or serotonin concentrations were not affected. ncreased dopamine 
concentrations were associated with increased tyrosine hydroxylase protein levels, indicating that 
dopamine synthesis is increased in these mice. An important finding was that increased RET 
activity increased the number of nigrostriatal dopamine neurons in the adult mice. n addition, 
acute cocaine administration increased the locomotor activity more in mice with increased RET 
activity than in their wild-type littermates. 
All in all, the present findings emphasize the important role of GDNF/RET-signalling in 
the regulation of brain dopaminergic systems. These results suggest that reduced brain GDNF 
levels alter the response of dopaminergic systems to morphine and the results further substantiate 
the importance of RET tyrosine kinase as a signalling receptor of GDNF in the dopaminergic 
system.
V
ABBREVATONS 
ANOVA   analysis of variance
ARTN    artemin
CNS   central nervous system
COMT    catechol-O-methyltransferase
CPP   conditioned place preference
DAT   dopamine transporter
DOPAC   3,4-dihydroxyphenylacetic acid
FMTC   familial medullary thyroid carcinoma
GABA    γ-aminobutyric acid
GDNF    glial cell line-derived neurotrophic factor
GDNF+/-  heterozygous GDNF knockout mice
GFRα   GDNF family receptor alpha
5-HAA    5-hydroxyindoleacetic acid
HVA    homovanillic acid
i.p.    intraperitoneal
L-DOPA  L-hydroxyphenylalanine   
MAO    monoamine oxidase
MEN 2    multiple endocrine neoplasia type 2
MEN2B/+  heterozygous MEN2B mice with Met919Thr mutation
MEN2B/MEN2B  homozygous MEN2B mice with Met919Thr mutation
3-MT    3-methoxytyramine
MPTP    1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
NCAM   neural cell adhesion molecule
NRTN   neurturin
6-OHDA   6-hydroxydopamine
PSPN    persephin
RET   rearranged during transfection
s.c.    subcutaneous
SEM    standard error of the mean
SN   substantia nigra
SNpc   substantia nigra pars compacta
SNpr    substantia nigra pars reticulata
TH   tyrosine hydroxylase
VMAT   vesicular monoamine transporter
VTA    ventral tegmental area
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11. INTRODUCTION
Addiction to drugs of abuse is a major 
social and health care problem world-wide. 
n the United States and Western Europe, 
epidemiology surveys report that there are 
about 30 million individuals with drug or 
alcohol addiction (Pouletty, 2002). The 
economic costs of substance abuse are high. 
The cost of heroin addiction in the United 
States in 1996 was estimated to be US$21.9 
billion, of which 53% was productivity loss, 
24% criminal activities, 23 % medical care 
and only 0.1% social welfare costs (Mark et 
al., 2001). The economic costs of all abused 
drugs in the United States in 2002 was 
estimated to be US$180.9 billion of which 
71.2% was loss of productivity (Office of 
National Drug Control Policy, 2004). To 
develop new drugs for addiction disorders, 
researchers face the important challenge of 
understanding the cellular and molecular 
mechanisms in the development of addiction. 
Novel approaches must be explored to find 
new treatment strategies. Neurotrophic 
factors are involved in plastic changes in the 
central nervous system (CNS). They may 
be involved in long-term responses to drug 
exposure, and are the focus of the studies 
reported upon herein. 
Neurotrophic factors are endogenous 
proteins that have been studied for their role in 
neuronal growth, survival and differentiation 
during development. Nerve growth factor 
(NGF) was the first neurotrophic factor, 
identified by Rita Levi-Montalcini, Viktor 
Hamburger and Stanley Cohen in the 1950s 
(Levi-Montalcini, 1987). n the beginning of 
the 1990s, glial cell line-derived neurotrophic 
factor (GDNF) was purified from a rat 
glioma cell-line supernatant and was found to 
promote survival of mesencephalic dopamine 
neurons in vitro (Lin et al., 1993). Since then, 
the effects of GDNF on brain dopaminergic 
systems have been extensively studied, and it 
is an important candidate for drug targeting 
in Parkinson’s disease (for review, see Kirik 
et al., 2004). Brain dopaminergic pathways 
are critically involved in drug reward and 
undergo changes during chronic drug use. 
GDNF has, therefore, been of interest also 
for treatment of drug addiction and there are 
indications that GDNF, administered to the 
brain, may be able to reduce the biochemical 
and behavioural changes induced by drugs 
of abuse (Green-Sadan et al., 2003�� Green-    
Sadan et al., 2005�� He et al., 2005�� Messer 
et al., 2000). Thus, GDNF and its signalling     
pathway might be novel targets for developing 
drugs for addictive disorders. 
Drug addiction is a complex disorder 
of the brain and has a variety of causes. 
Vulnerability to addiction is increased 
by certain genetic factors, environmental 
influences and by drug-induced changes in 
the brain (Kreek et al., 2005). Addiction is 
a behavioural response to the biochemical 
actions of drugs of abuse in the brain and 
its development requires repeated drug 
exposure. Addictive drugs alter behaviour, 
and casual drug use may progress to addiction. 
Transition from casual to compulsive patterns 
of drug use is thought to have its basis in the 
neural processes mediating drug-seeking 
behaviour (Robinson and Berridge, 2003). 
The transit from use to addiction involves 
many drug-induced changes in the brain and 
corresponding behavioural adaptations. The 
activation of dopaminergic pathways in the 
brain is considered to play a central role in 
the rewarding effects of drugs of abuse, and 
most importantly, the brain dopaminergic 
systems are involved in learning processes, 
such as in the formation of connections 
between contextual stimuli and rewarding or 
aversive events (Spanagel and Weiss, 1999). 
2The objectives of the present 
experiments were to study the involvement 
of GDNF/RET-signalling in the function 
and regulation of cerebral dopaminergic 
systems and its role in the development of 
drug addiction. The research aimed to clarify 
the physiological role of endogenous GDNF 
in the regulation of brain dopaminergic 
systems. The studies also explored how 
reduced endogenous GDNF levels are 
involved in the effects of acute and repeated 
administration of cocaine and morphine. 
Also, the studies explored the common 
GDNF-family ligand RET tyrosine kinase 
receptor and how its constitutive activity 
affects cerebral dopaminergic systems. This 
research was based on the hypothesis that 
reduced GDNF-RET-signalling will lead 
to similar changes in the brain, that are 
seen following repeated exposure to drugs 
of abuse, which will lead to a sensitization 
to the effects of cocaine or morphine. 
Alternatively, we hypothesized that the 
constitutive RET signalling and activity 
protects and maintains brain dopaminergic 
systems. 
32. REVIEW OF THE LITERATURE
2.1. Brain dopaminergic systems
n the late 1950s, Carlsson and co-workers 
found that dopamine is an independent 
neurotransmitter in the brain and not just a 
precursor in the synthesis of adrenaline and 
noredrenaline (Carlsson et al., 1957�� Carlsson 
et al., 1958�� Carlsson, 1959). Dopamine is 
involved in many CNS functions including 
locomotor behaviour, emotions, congnition 
and endocrine regulation.
As shown in Figure 2.1, the cell bodies 
of the neurons forming major ascending 
dopaminergic pathways are located in the 
ventral midbrain, in the subtantia nigra pars 
compacta (SNpc, A9) and in the ventral 
tegmental area (VTA, A10). The A9 neurons 
project mainly to the caudate/putamen, 
also known as dorsal striatum, forming the 
nigrostriatal dopaminergic pathway (Fuxe 
et al. 1985). The A10 neurons project 
mainly to the ventral striatum (e.g. nucleus 
accumbens, and olfactory tubercle) and 
other limbic regions, such as amygdale, 
and hippocampus forming the mesolimbic 
dopaminergic pathway (Fuxe et al. 1985). 
The nucleus accumbens can be divided 
into two subdivisions: the shell and the 
core. The latter is surrounded on its medial 
and ventral sides by the shell (de Olmos 
and Heimer, 1999). The core is similar to 
the rest of the striatal complex, whereas 
the shell is similar to and a continuum 
of the extended amygdala. The extended 
amygdala is comprised of the shell of the 
nucleus accumbens, the bed nucleus of 
stria terminalis and the central nucleus 
of amygdala (Heimer et al., 1991). Also 
the mesocortical dopaminergic pathway 
originates from the A10 area. This pathway 
projects to limbic cortical areas, e.g. the 
medial prefrontal cortex, cingulate cortex 
and entorhinal areas.
n addition to the long ascending 
pathways described above, there are local 
ultrashort and intermediate length central 
dopaminergic pathways. ntermediate length 
central dopaminergic pathways include the 
tuberoinfundibular system, which originates 
from arcuate and periventricular nuclei 
(A12) and projects to median eminence 
and neurointermediate lobe of the pituitary. 
This tuberoinfundibular system is involved 
in the regulation of pituitary hormone 
release, particularly prolactin (for review, see 
Tuomisto and Männistö, 1985). Ultrashort 
systems include interplexiform amacrine-like 
neurons, which originate from the A17 area 
in the retina, and periglomerular dopamine 
cells, which originate from the A16 area in 
the olfactory bulb (Fuxe et al. 1985). This 
thesis is focused only on long ascending 
dopaminergic pathways described above. 
The nigrostriatal pathway is involved 
in the control of motor behaviour, control 
of posture, maintaining automatic motor 
functions and learning of habits. Loss 
of striatal dopamine by destruction of 
nigrostriatal dopaminergic neurons causes 
extrapyramidal symptoms and signs of 
Parkinson’s disease (Carlsson, 1959). The 
mesolimbic and mesocortical dopaminergic 
systems are involved in the control of 
motivation, emotions and reward, as well 
as in the control of motor behaviour. These 
two systems mediate the reinforcing actions 
of both natural rewards and abused drugs, 
such as cocaine, amphetamine, opioids 
and alcohol, which increase extracellular 
dopamine concentrations in the nucleus 
accumbens (Di Chiara and mperato, 1988�� 
Spanagel and Weiss, 1999). n addition, there 
is evidence that schizophrenia is associated 
4with abnormalities in the mesolimbic system 
(Carlsson et al., 2001). The hypothesis of 
excessive dopaminergic activity in limbic 
brain regions is based on the therapeutic 
effects of classical antipsychotic drugs, 
which block dopamine D2-like
 
receptor, 
and that dopamine releasing drugs, such as 
amphetamine, can cause psychosis. 
The vast majority of striatal neurons 
are medium-sized spiny projection neurons 
(Harlan and Garcia, 1998). They contain 
γ-aminobutyric acid (GABA) and can be 
subclassified according to the neuropeptides 
they produce. Approximately 50-60% 
express preproenkephalin which encodes 
a proenkephalin, which is cleaved into the 
active opioid neuropeptides methionine 
enkephalin and leucine enkephalin. A smaller 
proportion of medium-sized spiny projection 
neurons express preprotachykinin, which 
encodes the precursor of the neuropeptides 
substance P and neurokinin A. Many of 
these neurons also express preprodynorphin, 
which is the precursor of dynorphins A and B. 
Enkephalins and dynorphin are endogenous 
opioid peptides. They signal through µ-, δ- 
and κ-type opioid receptors. n the striatum 
about 90% of neurons have been classified as 
medium-sized spiny projection neurons and 
about 10% have been identified as aspiny 
interneurons, of which 1% can be classified 
as cholinergic and majority as GABAergic 
interneurons (Kawaguchi et al., 1995). 
GABAergic interneurons are local neurons 
that express, among others, calcium-binding 
proteins or neuronal nitric oxide synthase. 
As shown in Figure 2.1, efferent 
GABAergic neurons project from the 
Figure 2.1. (A) Schematic representation of the ascending dopaminergic pathways originating 
from the substantia nigra pars compacta (SNpc, A9) and the ventral tegmental area (VTA, 
A10). (B) Simplified presentation of postsynaptic neurons in the striatum and projections of 
the medium-sized spiny GABAergic projection neurons. Continuous black lines represent 
dopaminergic pathways, grey lines represent GABAergic pathways, grey broken lines represent 
glutamatergic pathways. PfC= prefrontal cortex, NAc= nucleus accumbens, OT= olfactory 
tubercle, CPu= caudate putamen, CNA= central nucleus of amygdala. GPe= external segment of 
globus pallidus, STN= subthalamic nuclues, SNr= substantia nigra pars reticulata, SP= substance 
P, Dyn=dynorphin, enk=enkephalin, GABA int = aspiny GABAergic interneuron, Ach int= 
cholinergic interneuron. A is modified from Fuxe et al. 1985.�� B from Alexander and Crutcher, 
1990�� Heimer et al., 1991�� Kalivas et al., 1999�� Zhou et al., 2003. 
5dorsal striatum to the substantia nigra pars 
reticulata (SNpr) directly or indirectly via 
the external segment of the globus pallidus 
and subthalamic nucleus (Alexander and 
Crutcher, 1990). From the SNpr, there are 
projections to the thalamus, from which there 
are projections to the dorsal striatum and 
cortical areas. These projections constitute 
a cortico-striatal-pallido-thalamic loop. 
This circuitry is involved in the regulation 
of extrapyramidal motor processes. Efferent 
GABAergic projection neurons from the 
core and the shell of the nucleus accumbens 
differ. Both project to the ventral pallidum, 
but with a distinct topography. The core 
projection is located in the dorsolateral 
part of the ventral pallidum, whereas the 
shell projection is located in the medial part 
of the subcommissural ventral pallidum 
(Heimer et al., 1991). The projections 
from nucleus accumbens subdivisions to 
the ventral midbrain are also different, as 
the ones from the core project mainly to 
the substantia nigra (SN), while those from 
the shell project to the VTA (Heimer et al., 
1991). 
Besides dopaminergic inputs, the 
striatum is regulated by glutamatergic 
inputs. The dorsal striatum receives 
glutamatergic afferents from the entire 
neocortical area, whereas the nucleus 
accumbens receives glutamatergic afferents 
from several brain regions including 
prefrontal cortex, basolateral amygdala, 
hippocampus and thalamus (West et al., 
2003). The main targets of glutamatergic 
inputs in the striatal area are the GABAergic 
medium-sized spiny projection neurons. n 
addition, glutamatergic and dopaminergic 
transmission interacts via pre- and 
postsynaptic mechanisms as a functionally 
related network to control striatal output 
(Descarries et al., 1996). 
2.1.1. Synthesis and metabolism of 
dopamine
Dopamine and other catecholamines are 
synthesised from the amino acid tyrosine 
(Figure 2.2.). Tyrosine is first converted to L-
dihydroxyphenylalanine (L-DOPA) by the 
rate limiting enzyme tyrosine hydroxylase 
(TH, Carlsson and Lindqvist, 1978�� Levitt 
et al., 1965). Then L-DOPA is rapidly 
converted to dopamine by aromatic L-amino 
acid decarboxylase. Synthesized dopamine is 
taken by vesicular monoamine transporter 
(VMAT) and stored in nerve terminal vesicles 
or metabolized by monoamine oxidase 
(MAO) to 3,4-dihydroxyphenylacetic 
acid (DOPAC), which diffuses out of the 
neurons. From synaptic vesicles, dopamine 
is released in a calcium-dependent manner 
when an action potential reaches the nerve 
terminal. Most of the released dopamine 
is taken up into the dopaminergic neurons 
by the membrane dopamine transporter 
(DAT). Synaptic dopamine can interact with 
its receptors, and in addition, it has been 
suggested that there is another uptake system 
(uptake
2
) located in the cell membranes of 
glial cells and possibly in the cell membranes 
of postsynaptic cells (Trendelenburg, 1989�� 
Wilson et al., 1988). n the postsynaptic 
neurons or in the glial cells dopamine is 
converted into methoxytyramine (3-MT) 
by catechol-O-methyltransferase (COMT). 
COMT is found in soluble and membrane 
bound forms (Lundström et al., 1991�� 
Salminen et al., 1990) and in the striatum 
COMT is found in the postsynaptic neurons, 
astro glial cells and also in the microglial cells 
(Kaakkola et al., 1987�� Karhunen et al., 1995�� 
Reenilä et al., 1997). n addition, dopamine 
is converted by MAO into DOPAC and, 
furthermore, 3-MT and DOPAC are 
converted into homovanillic acid (HVA, 
Figure 2.2). Both isoforms of MAO, MAO
A 
6Figure 2.2. Schematic model of dopaminergic synapse and dopamine metabolism. Dopamine is 
synthesized from amino acid tyrosine. Tyrosine is first converted to L-DOPA by the rate limiting 
enzyme tyrosine hydroxylase (TH), and thereafter, L-DOPA is converted into dopamine by 
L-amino acid decarboxylase (DDC). n the nerve terminals, dopamine is stored in vesicles by 
vesicular monoamine transporters (VMAT) or metabolized by monoamine oxidase (MAO
A
) 
to 3,4-dihydroxyphenylacetic acid (DOPAC). Synaptic dopamine may interact with pre- or 
postsynaptically located dopamine receptors. Most of the released dopamine is taken up by 
dopamine transporters (DAT) into presynaptic dopaminergic cells, but dopamine is also taken 
up by uptake systems associated with glial or postsynaptic cells (uptake2). Homovanillic acid 
(HVA) is metabolized sequentially from DOPAC or 3-methoxytyramine (3-MT) by catechol 
o-methyltransferase (COMT) and MAO, respectively. Dopamine D1 receptors are preferentially 
expressed in GABAergic neurons co-expressing substance P (SP) and dynorphin (DYN) whereas 
dopamine D2 receptors are present on dopaminergic terminals (autoreceptors) and preferentially 
on postsynaptic GABAergic neurons expressing enkephalins (enk). Figure modified from 
Törnwall 1994�� Youdim et al. 2006.  
7and MAO
B
, are involved in metabolism of 
dopamine and they are located intracellularly 
in the outer membrane of mitochondria 
(for review, see Youdim et al., 2006). n 
the striatam, MAO
A
 is found mainly in 
dopaminergic neurons and in glial cells and 
MAO
B
 is found found mainly in glial cells. 
n mice, dopamine is metabolized by MAO
A
 
under basal conditions and by both MAO
A
 
and MAO
B
 at high dopamine concentrations 
(Fornai et al., 1999). n humans and in 
primates, dopamine is also metabolized by 
both MAO forms (Di Monte et al., 1996�� 
Glover et al., 1977). 
2.1.2. Dopamine receptors
Dopamine receptors belong to the family 
of seven transmembrane domain G-protein 
coupled receptors and they are classified as 
D1- and D2-like receptors (for review, see 
Missale et al., 1998). The D1-like family 
contains D1 and D5 receptors and the 
D2-like family contains D2, D3 and D4 
receptors. The activation of D1-like receptors 
increase adenylate cyclase activity whereas 
the activation of D2-like family receptors 
decrease adenylate cyclase activity, suppress 
Ca2+ currents and increase K+ currents.
D1 receptors are the most widely 
expressed dopamine receptors in the brain. 
n the dopaminoceptive regions, they are 
highly expressed in caudate/putamen, 
nucleus accumbens, olfactory tubercle and 
amygdale. n the striatum, D1 receptors are 
located mainly on GABAergic neurons co-
expressing substance P (Gerfen et al., 1990). 
Compared to D1 receptors, D5 receptors are 
much less widely expressed in the rat brain. 
D5 receptor mRNA is mainly expressed in 
forebrain regions. D2 receptors are widely 
expressed in the brain, overlapping with the 
distribution of D1 receptors. D2 receptors 
are highly expressed postsynaptically in the 
caudate/putamen, nucleus accumbens and 
in the olfactory tubercle, where they are 
mainly expressed in GABAergic medium-
sized spiny projection neurons coexpressing 
enkephalins (Le Moine et al., 1990). n the 
nucleus accumbens, D2 receptors are mainly 
expressed in the core of the nucleus accumbens 
and only in restricted parts of the shell (Diaz 
et al., 1994). D3 receptors are absent from 
the dorsal striatum and are mainly expressed 
with high density in the shell of the nucleus 
accumbens on GABAergic medium-sized 
spiny projection neurons co-expressing 
neurotensin mRNA (Diaz et al., 1994).
Besides their postsynaptic localization, 
D2 receptors are also located presynaptically 
on dopamine neurons and referred to as 
autoreceptors. Dopamine autoreceptors 
in nerve terminals modulate synthesis and 
release of dopamine whereas autoreceptors 
located in somatodendritic regions modulate 
neuronal firing. Somatodendritically released 
dopamine (Cheramy et al., 1981) from the 
SNpc can either act on somatodendritic D2 
autoreceptors or postsynaptically on D1 
receptors in the SNpr. n SNpr, D1 receptors 
are on GABAergic cells and they control 
GABA release, which has an inhibitory effect 
on dopaminergic neurons. As D1 receptors 
are located mainly extrasynaptically (Caille 
et al., 1996), it has been proposed that more 
massive striatal dopamine output is needed 
for their activation than for that of D2 
receptors. 
2.1.3. Electrophysiological properties of 
dopaminergic neurons
Dopaminergic neurons originating from 
SNpc or from VTA exhibit two main patterns 
8of activity, single spike firing and burst firing. 
Dopamine release can be divided into high-
amplitude transient phasic dopamine release 
mediated by burst firing of dopaminergic 
neurons and constant low-level tonic 
dopamine release regulated by baseline 
firing (Grace and Bunney, 1984a�� Grace and 
Bunney, 1984b). The bursting mode leads 
to a much larger dopamine release than in 
the single spike mode (Gonon, 1988). 
2.2. Neurotrophic factors and 
development of dopamine neurons
Neurotrophic factors are secreted proteins 
that bind to and activate their specific 
receptors on the cell surface. The classical 
neurotrophic factor concept states that 
limited amounts of available neurotrophic 
factors regulate the number of developing 
neurons (Levi-Montalcini, 1987). 
Neurotrophic factors are secreted by target 
tissues, are taken up by nerve terminals, and 
are transported in a retrograde manner to 
the cell bodies. Those neurons that receive 
survival-promoting neurotrophic proteins 
maintain synaptic connections with their 
neighbouring cells, while those that do not 
receive neurotrophic factors are not able to 
make synaptic connections and die largely by 
apoptosis. Originally, the neurotrophic factor 
hypothesis was proposed for the peripheral 
nervous system and it has been more recently 
adapted for the CNS. However, it is likely 
that in the CNS, the signalling cascades 
regulating cell survival are more complex. 
n the CNS, several neurotrophic factors 
may be involved in the regulation of certain 
neuronal phenotypes, and trophic support 
is delivered from diverse sources rather than 
only from the target. Besides regulating the 
number of neurons, neurotrophic factors 
have also been proposed to be involved in 
several aspects of neuronal functions, such as 
neurite branching, synaptogenesis, synaptic 
plasticity and electrophysiological properties 
(for review, see Sariola and Saarma, 2003). 
During the past several years, neurotrophic 
factors have been postulated as novel 
treatment strategies for diseases in which 
neuronal function is disturbed, such as spinal 
cord injury, neurodegenerative disorders 
(Parkinson’s disease, Alzheimer’s disease, 
amyotrophic lateral sclerosis), neuropathic 
pain, stroke and drug addiction. 
n order to promote survival of 
dopaminergic neurons during maturation, 
the expression of neurotrophic factors 
should be detectable during critical periods 
of development. t has been suggested 
that dopaminergic neurons in the SN of 
rat undergo biphasic cell death during 
development, at postnatal days 2 and 14 
(Oo and Burke, 1997). Thus, it is likely that 
neurotrophic factors regulate the number 
of dopaminergic neurons. Five established 
neurotrophic factors may be considered 
as a target-derived neurotrophic factor for 
dopaminergic neurons: Glial cell line-derived 
neurotrophic factor (GDNF), neurturin 
(NRTN), brain-derived neurotrophic factor 
(BDNF), neurotrophin-4 and fibroblast-
growth factor-2 (FGF-2) (Krieglstein, 
2004). 
2.3. The GDNF family of neurotrophic 
factors 
GDNF was identified from a rat glial 
cell line (B49) by its ability to increase 
dopamine uptake and to promote survival 
of dopaminergic neurons in embryonic 
midbrain cultures (Lin et al., 1993). GDNF 
is a glycosylated and disulfide-bonded protein 
having seven cysteine residues with the same 
9relative locations as the other members of 
the transforming growth factor (TGF) -β 
superfamily (Lin et al., 1993). Although it 
belongs to the TGF-β superfamily, its amino-
acid sequence homology as compared with 
other members of the family is low. GDNF 
is synthesized in a prepro-form of 211 amino 
acids, and the mature protein consists of 134 
amino acids. The GDNF-family consists of 
GDNF, neurturin (NRTN) (Kotzbauer et 
al., 1996), persephin (PSPN) (Milbrandt 
et al., 1998) and artemin (ARTN) (Baloh 
et al., 1998). All the GDNF-family ligands    
are basic and dimeric molecules and they 
are synthesized, secreted and activated by a 
variety of tissues in a prepro-form (Airaksinen 
et al., 1999). 
As GDNF was first shown to promote 
survival of dopamine neurons, it has been the 
most extensively studied neurotrophic factor 
regulating the brain dopaminergic system. 
GDNF is not specific for dopaminergic 
neurons, and has effects on many types 
of cells inside and outside of the CNS. 
GDNF has been shown to promote the 
survival of central noradrenergic neurons 
(Arenas et al., 1995), central serotonergic 
neurons (Cass, 1996), spinal motor neurons 
(Henderson et al., 1994), peripheral sensory 
and autonomic neurons (Trupp et al., 1995) 
and forebrain cholinergic and GABAergic 
neurons (Williams et al., 1996). Gene 
knockout studies have shown that GDNF is 
essential for the development of the kidney, 
the enteric nervous system and sympathetic 
cervical ganglia (Moore et al., 1996�� 
Pichel et al., 1996�� Sanchez et al., 1996). 
Moreover, GDNF is crucially involved in 
spermatogenesis (Meng et al., 2000).
NRTN was originally identified 
because of its ability to promote the survival 
of sympathetic neurons (Kotzbauer et al., 
1996), and, afterwards, it has been shown 
to promote the survival of spinal cord 
motoneurons, forebrain cholinergic neurons 
(Golden et al., 2003), retinal ganglion cells 
(Koeberle and Ball, 2002), enteric neurons 
(Heuckeroth et al., 1998) and substantia 
nigra dopaminergic neurons (Åkerud et 
al., 1999�� Horger et al., 1998�� Tseng et 
al., 1998). PSPN promotes the survival of 
ventral midbrain dopaminergic neurons and 
motor neurons but, in contrast to GDNF 
and NRTN, it appears to have no effects in 
the peripheral nervous system (Milbrandt et 
al., 1998). However, PSPN receptor, GDNF 
family receptor-α4, signalling is involved in 
regulation of calcitonin production in thyroid 
C cells. The most recently identified member 
of the GDNF-family, ARTN, promotes the 
survival of sensory and sympathetic neurons 
in vitro and in vivo (Baloh et al., 1998�� 
Airaksinen and Saarma, 2002). 
2.3.1. The GDNF family receptors and  
RET-dependent signalling
The common signalling receptor for all GDNF 
family ligands is the RET (REarrangement 
during Transformation) tyrosine kinase 
receptor (Durbec et al., 1996�� Treanor et al., 
1996�� Trupp et al., 1996). All GDNF family 
ligands first bind to their corresponding 
GDNF family receptor-α (GFRα) protein 
forming a high affinity complex. GDNF, 
NRTN, ARTN and PSPN specifically bind 
to GFRα1, GFRα2, GFRα3 and GFRα4, 
respectively (Airaksinen and Saarma, 2002). 
The GFRα1-receptor has been shown to 
exist as bound to the plasma membrane by 
a glycosylphosphatidylinositol anchor, but it 
has also been shown to be biologically active 
in a soluble form (Paratcha et al., 2001). 
Homodimeric GDNF binds to either 
monomeric or dimeric GFRα1�� the complex 
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brings two RET molecules together, and 
tyrosine residues in the intracellular domains 
of the RET proteins are autophosphorylated 
(Figure 2.3). 
Phenotypes of mice lacking GDNF, 
GFRα1 or RET are similar. Homozygous 
knockout mice die shortly after birth, lack 
kidneys and have abnormalities in their 
enteric nervous systems (Enomoto et al.,   
1998�� Moore et al., 1996�� Pichel et al., 
1996�� Sanchez et al., 1996�� Schuchardt et 
al., 1994��). RET  has been shown to have 
two spliced variants, the RET51 and RET9 
isoforms (Tsui-Pierchala et al., 2002). t has 
been suggested that only RET9 is critical for 
life�� it is important for normal development 
of kidneys and the enteric nervous system 
(de Graaff et al., 2001). However, the role 
of RET51 and RET9 in the regulation of 
kidney development is not clear, as recently 
it has been reported both homozygous 
RET9 and RET51 mice have normal 
kidney development (Jain et al., 2006). The 
intracellular domain of RET consists of 14 
tyrosine residues, and phosphorylated tyrosine 
residues Tyr905, Tyr1015, Tyr1062 and Tyr1096 are 
docking sites for adaptor proteins (Airaksinen 
and Saarma, 2002). RET activates several 
intracellular signalling cascades, including 
the mitogen activated protein kinase 
pathway, phosphoinositide 3-kinase pathway, 
Src-family kinases and phospholipase Cγ 
that regulate cell survival, differentiation, 
proliferation, neurite outgrowth and synaptic 
plasticity (Airaksinen and Saarma, 2002�� 
Sariola and Saarma, 2003).
RET was originally described as an 
oncogene (Takahashi et al., 1985). n 
Figure 2.3. GDNF-family ligands and their receptors. Homodimeric GDNF-family ligand/GFRα-
receptor complexes induce dimerization of two RET molecules, leading to transphosphorylation 
of their tyrosine kinase domains. All ligands activate RET via specific GFRα co-receptors. Four 
tyrosine residues (Tyr905, Tyr1015, Tyr1062, Tyr1096) serve as docking sites for different 
adaptors (Tyr1096 is only in the long isoform of the RET). 
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humans, heterozygous activating mutations 
in the RET gene are found in a dominantly 
inherited cancer syndrome called multiple 
endocrine neoplasia type 2 (MEN2), and 
heterozygous inactivating mutations of 
RET cause Hirschsprung’s disease (Edery et 
al., 1997�� Santoro et al., 2004�� Takahashi, 
2001). There are three clinical subtypes 
of the MEN2-syndrome called MEN2A, 
MEN2B and familial medullary thyroid 
carcinoma (FMTC). MEN2A patients are 
affected by medullary thyroid carcinoma, 
and pheochromocytoma and parathyroid 
hyperplasia are present in about 50% 
and 15-30%, respectively, of the patients 
(Santoro et al., 2004). MEN2B patients 
suffer from medullary thyroid carcinoma, 
pheochromocytoma (about 50% of the 
patients) and, rarely, ganglioneuromas in the 
intestine. n MEN2A patients, mutations of 
RET affect the extracellular domain of the 
RET receptor and lead to its activation by 
covalent RET dimerization. The MEN2B-
syndrome is associated primarily with a 
single activating, missense mutation of 
codon 918 (Met918Thr) affecting the 
catalytic intracellular tyrosine kinase 
domain (Takahashi, 2001). FMTC patients 
suffer from medullary thyroid carcinoma. 
Hirschsprung’s disease is characterized by 
magacolon and absence of enteric ganglia. 
2.3.2. Other mechanisms of GDNF 
signalling 
GFRα receptors have been also found in 
brain regions where RET is not seen, and 
it has been proposed that GDNF/GFRα1 
also signals independently of RET. n the 
adult midbrain of rodents, the expression 
patterns of GFRα1 and RET are similar, 
but, for example, in the cortex and GFRα1 
is present but RET is absent (Golden et al., 
1998�� Trupp et al., 1997). n the nervous 
system, neural cell adhesion molecule 
(NCAM) is abundantly expressed in cell 
types that express GFRα1 but not RET, 
including cortical and hippocampal neurons 
(Crossin and Krushel, 2000). ndeed, it has 
been demonstrated that NCAM functions as 
an alternative signalling receptor for GDNF 
(Paratcha et al., 2003). n addition, ventral 
midbrain dopaminergic neurons also express 
NCAM, along with GFRα1 and RET, and 
neutralizing NCAM antibodies block the 
effects of GDNF on enhanced dopamine 
turnover and locomotor activity (Chao et 
al., 2003). 
2.3.3. Co-operation of GDNF with other 
proteins
TGF-β has been shown to be important for the 
functional effects of GDNF. GDNF requires 
TGF-β for exerting its full neurotrophic 
potential on cultured peripheral autonomic, 
sensory and midbrain dopaminergic neurons 
(Krieglstein et al., 1998). The effects of GDNF 
are abolished when neutralizing antibodies 
to endogenous TGF-β are added. n TGF-β/
GDNF synergistic signalling, TGF-β recruits 
GFRα1 to the plasma membrane and is 
involved in its glycosylphosphatidylinositol 
anchoring (Peterziel et al., 2002). n 
addition, brain-derived neurotrophic factor 
(BDNF) has been shown to be needed for 
the survival-promoting effect of GDNF on 
primary sensory neurons (Erickson et al., 
2001). Also, GDNF signalling requires cell 
surface heparin sulphate glycosaminoglycans. 
Without heparin sulphate, GDNF does not 
fully activate the RET receptor, nor does 
it fully induce axonal growth or scattering 
of epithelial cells (Barnett et al., 2002). 
The idea of heparin sulphate/GDNF co-
operation is also supported by the finding 
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that, similar to homozygous GDNF, GFRα 
and RET knockout mice, mice lacking 
heparin sulphate also lack kidneys (Bullock 
et al., 1998). 
2.3.4. GDNF, GFRα1 and RET 
expression 
Table 2.1 summarizes information on GDNF, 
GFRα1 and RET mRNA and protein 
expression in dopaminergic brain regions and 
in areas related to dopaminergic circuitry. 
During development, GDNF mRNA is 
widely expressed in the brain and outside 
the nervous system. GDNF mRNA is highly 
expressed in developing skin, whisker pad, 
kidney, stomach and testicle (Choi-Lundberg 
and Bohn, 1995�� Trupp et al., 1995). n the 
striatum, the highest levels are on postnatal 
day (P) 0 and P10 (Choi-Lundberg and 
Bohn, 1995)�� in addition, GDNF mRNA is 
found in the hippocampus and in the globus 
pallidus during the development. The pattern 
of expression is similar in the adult brain, 
although the levels are lower. GFRα1 and 
RET are co-localized in developing and in the 
adult ventral midbrain. However, RET is not 
expressed in the striatum, ventral pallidum 
or globus pallidus. During development, 
the RET receptor is widely expressed in 
embryonic retina, kidney, autonomic and 
dorsal root ganglia, motor neurons of the 
spinal cord, enteric neurons, thyroid and 
testicle (Golden et al., 1998�� Pachnis et al., 
1993�� Tsuzuki et al., 1995). n striatal brain 
areas, GFRα1 mRNA is not expressed, but 
in the dorsal striatum there are low levels of 
GFRα1 protein found. n the hippocampus 
and ventral pallidum, GFRα1 mRNA 
and protein are found and the protein has 
also been detected in the globus pallidus. 
GFRα1 mRNA and protein expression in 
the midbrain differ. GFRα1 mRNA is highly 
expressed in the SNpc and in the VTA, but 
protein is highly expressed in SNpc and SNpr 
and only at low levels in the VTA. 
All GDNF-family ligands are produced 
in a prepro precursor form. The pre-sequence  
is cleaved during secretion, and the pro-
form removal occurs by proteolytic cleavage 
(Airaksinen and Saarma, 2002). Regulation 
of GDNF synthesis is only partially known. 
n the nervous system, GDNF mRNA has 
been localized to both glial cells and neurons 
(Schaar et al., 1993), and, thus, GDNF 
might act on brain dopaminergic neurons 
as a paracrine factor and as a target-derived 
factor. Localization studies of GDNF in the 
striatum have shown that GDNF mRNA 
is localized mainly in striatal cholinergic 
interneurons, to a lesser extent in GABAergic 
interneurons, and also possibly in medium-
sized GABAergic projection neurons (Bizon 
et al., 1999). This has also been supported by 
the finding that GDNF mRNA is expressed 
throughout the striatum in medium-sized 
neurons at low levels, whereas other striatal 
neurons express clearly higher levels (Trupp 
et al., 1997). However, in one study it was 
reported that in the developing postnatal brain 
of a rat, GDNF mRNA is expressed mainly in 
striatal GABAergic projection neurons (Oo 
et al., 2005). Studies exploring the transport 
of GDNF protein have shown that in adult 
brain, GDNF is retrogradely transported 
from striatum to SNpc (Georgievska et al., 
2004�� Tomac et al., 1995b), but only about 
half of the nigral dopaminergic neurons 
expressed GDNF (Tomac et al., 1995b). 
Thus, as a transport mechanism is present in 
adult brain, it is likely that GDNF is involved 
in maintenance of dopaminergic neurons. 
There seems to be an interaction 
between dopamine D2 receptors and GDNF 
synthesis, since in D2 receptor knockout 
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mice, GDNF concentrations in the striatum 
are decreased (Bozzi and Borrelli, 1999). 
n addition, in mouse astrocytes, high 
concentrations of the dopamine D2 receptor 
agonist, bromocriptine, have been shown to 
decrease GDNF levels while the dopamine D1 
receptor agonist SKF38393 has been shown 
to increase GDNF levels (Ohta et al., 2003). 
GDNF synthesis is differently regulated in 
glial and neuronal cells. Proinflammatory 
cytokines, such as interleukin-1β and tumor 
necrosis factor-α have been shown to increase 
GDNF synthesis in glioblastoma cells and 
to decrease its synthesis in neuroblastoma 
cells (Verity et al., 1999). n animal models 
of seizures (Humpel et al., 1994�� Kokaia 
et al., 1999) and ischemia (Kokaia et al., 
1999), GDNF expression is increased. 
Seizures are associated with glutamate release 
and glutamate has been shown to regulate 
GDNF expression in striatal astrocytes (Ho 
et al., 1995). n addition, fibroblast growth 
factors-1, -2 and -9 have been shown to 
increase GDNF expression in glioblastoma 
Table 2.1. mRNA and protein expression of GDNF, GFRα1 and RET in selected areas of 
developing and adult rodent brain. – indicates not detected, ± indicates barely detected, + low 
levels, ++ moderate levels, +++ high levels, empty cells indicate not measured�� SNpc= substantia 
nigra pars compacta, SNpr= substantia nigra pars reticulata, VTA= ventral tegmental area, CPu= 
caudate putamen, NAc= nucleus accumbens, Hipp= hippocampus, VP= ventral pallidum, GP= 
globus pallidus 
Table combined from the following references: a: (Golden et al., 1998), b: (Matsuo et al., 2000),    
c: (keda et al., 1999) d: (Burazin and Gundlach, 1999), e: (Trupp et al., 1997), f: (Nosrat et al.,        
1997), g�� (Nosrat et al., 1996), h: (Strömberg et al., 1993), i: (Golden et al., 1999), j: (Kokaia 
et al., 1999)
Developing 
brain
GDNF
mRNA
g, h, i
GDNF 
Protein
c
GFRα1
mRNA
d, f, i
GFRα1
protein
RET
mRNA
d, f, i
RET
protein
SNpc +++ +++ 
SNpr ± ±
VTA +++ +++ 
CPu ++ ++ - -
NAc ++ - -
Hipp ++ ++ ++ +
VP ++
GP ++ ++
Adult GDNF
mRNA
a, e
GDNF 
protein
GFRα1
mRNA
a, e, f
GFRα1
Protein
b, 
RET
mRNA
a, e, f, j
RET
Protein
f
SNpc - +++ +++ +++ +
SNpr - + +++ +
VTA - +++ + +++ +
CPu + - + -
NAc + - - -
Amygdale ± + ±
Hipp ++ ++ + +
VP + ++ +++ -
GP ± - ++ -
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cells (Suter-Crazzolara and Unsicker, 1996�� 
Verity et al., 1999). 
2.3.5. GDNF and the brain dopaminergic 
system
The physiological role of GDNF as a 
limiting, target–derived neurotrophic factor 
for dopaminergic neurons is not clear. 
Endogenous GDNF alone does not have 
a role in the embryonic development of 
dopaminergic systems as neither GDNF 
nor GFRα-1 homozygous knockout mice 
show any reduction in the number of 
dopaminergic neurons at birth (Enomoto et 
al., 1998�� Granholm et al., 1997�� Moore et 
al., 1996�� Pichel et al., 1996�� Sanchez et al., 
1996). However, as discussed above, during 
development, cell death of dopaminergic 
neurons is mainly postnatal (Oo and Burke, 
1997). The role of GDNF as a rate-limiting 
factor for dopaminergic neurons is supported 
by the fact that GDNF mRNA is expressed in 
the striatum at moderate levels during early 
postnatal development (Choi-Lundberg and  
Bohn, 1995�� Schaar et al., 1993�� Strömberg 
et al., 1993). n line with the hypothesis,     
GDNF suppressed the first phase of natural 
cell death of dopaminergic neurons in a 
postnatal primary culture model (Burke et al., 
1998), whereas injection of GDNF-activity 
blocking antibodies augments it (Oo et al., 
2003). Transplanting ventral midbrain grafts 
from GDNF-/- foetuses into the brain of adult 
wild-type mice markedly reduced dopamine 
neuron numbers and fiber outgrowth 
(Granholm et al., 2000). Transgenic mice 
overexpressing GDNF in the striatum have 
increased numbers of dopaminergic neurons 
in the SNpc after the first phase of natural cell 
death (Kholodilov et al., 2004). However, the 
number of dopaminergic neurons in the SNpc 
was not maintained up to adulthood in these 
mice, although their number was increased in 
the VTA (Kholodilov et al., 2004). Thus, it 
has been shown that GDNF has a role in the 
regulation of the postnatal development and 
survival of dopaminergic neurons. 
The effects of exogenous GDNF on 
intact dopaminergic neurons are widespread. 
t was first shown to promote the survival of 
mesencephalic dopamine neurons in vitro 
and to increase dopamine uptake (Lin et 
al., 1993). n addition, GDNF increases 
neurite outgrowth and cell size of TH-
positive neurons in vitro (Lin et al., 1993) 
and increases sprouting and the number 
of synaptic terminals in isolated ventral 
tegmental dopaminergic neurons of rat 
(Bourque and Trudeau, 2000�� Åkerud et 
al., 1999). n several studies it was found 
that GDNF enhances the release of striatal 
dopamine in vitro (Feng et al., 1999�� Lin 
et al., 1993�� Pothos et al., 1998). n several 
in vivo microdialysis studies with adult 
and aged rats and with aged primates, it 
was found that GDNF enhances stimulus-
evoked release of striatal and nigral 
dopamine (Grondin et al., 2003�� Hebert 
and Gerhardt, 1997�� Hebert et al., 1996�� 
Hoffman et al., 1997�� Salvatore et al., 2004�� 
Xu and Dluzen, 2000). n addition, a single 
GDNF injection into the SN or chronic 
perfusion into the lateral ventricle has been 
shown to increase motor activity (Grondin 
et al., 2003�� Hebert and Gerhardt, 1997�� 
Hebert et al., 1996�� Hudson et al., 1995�� 
Martin et al., 1996). As summarized in 
Table 2.2, the reported effects of GDNF on 
basal extracellular dopamine concentrations 
and on tissue dopamine concentrations are 
not all consistent. n several studies it has 
been shown that intranigral administration 
of GDNF decreases dorsostriatal tissue 
dopamine concentrations 2-3 weeks after 
the injection. However, when GDNF is 
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administered directly into the striatum the 
tissue dopamine content is increased after a 
latency period of 2-3 weeks. nterestingly, 
when GDNF is given unilaterally into the 
SN, the dopamine content has been found 
to be increased bilaterally in the nucleus 
accumbens of aged rats (Hebert and 
Gerhardt, 1997). n the developing postnatal 
brain, striatal GDNF injections clearly 
increase tissue dopamine concentrations 
in the striatum and in the SN (Beck et al., 
1996). 
n a neuroblastoma cell line, added 
GDNF increased TH mRNA expression, 
accompanied by increased protein levels, 
after 20-h incubation (Xiao et al., 2002). 
This is consistent with the findings that one 
week after intranigral GDNF administration 
TH-immunostaining in the striatum 
is increased and dopamine turnover is 
enhanced in the SN and in the striatum 
(Hudson et al., 1995�� Martin et al., 1996). 
The GDNF-induced enhanced dopamine 
turnover and stimulus-evoked dopamine 
Normal age rats, single administration
Injection 
site, dose, 
latency 
period
Extra-
cellular 
dopamine 
Extra-
cellular 
DOPAC
Extra-
cellular
HVA
Tissue dopamine Tissue DOPAC Tissue HVA
ntranigral, 
10µg,  
3 weeks
↑ CPu ipsilateral
↔ NAc
↓ SN ipsilateral
c
ntranigral, 
10µg,  
3 weeks
↔ CPu ↑ CPu ↑ CPu ↓ CPu ipsilateral
↔  SN
↔ CPu
↔ SN
↔ CPu
↔ SN
d
ntranigral, 
100µg,  
2 weeks
↓ CPu ipsilateral
↑ SN ipsilateral
↔ CPu
↑ SN ipsilateral
↔ CPu
↑ SN ipsilateral
e
ntrastriatal, 
10/100µg, 
2 weeks
↔ CPu ↑ CPu ↑ CPu ipsilateral ↑ CPu ipsilateral ↑ CPu ipsilateral e, f
Aged rats, single administration
ntranigral, 
10µg,  
3 weeks
↑ CPu
↑ NAc
↑ CPu
↑ NAc
↑ CPu
↑ NAc
↓ CPu ipsilateral
↑ NAc bilateral
↑ SN ipsilateral
↓ CPu ipsilateral
↔ NAc
↓ SN bilateral
↓ CPu ipsilateral
↑ NAc bilateral
a
Aged monkeys, chronic infusion
Lateral 
ventricle,  
7.5µg for  
3 months
↔ CPu
↑ SN
↔ CPu
↔ SN
↑ CPu
↔ SN
b
Table 2.2. Effects of acute administration of GDNF into SN or striatum on extracellular and 
tissue dopamine, DOPAC and HVA concentrations in normal and aged rats�� given is also the 
effect of chronic infusion into lateral ventricle in aged monkeys. Arrows indicate the increase or 
decrease of concentrations as compared with vehicle treatment��↔indicates that the concentration 
was not changed. Table combined from a: (Hebert and Gerhardt, 1997), b (Grondin et al., 
2003), c: (Hudson et al., 1995), d: (Hebert et al., 1996), e: (Martin et al., 1996), f: (Xu and                 
Dluzen, 2000). CPu= caudate putamen, NAc= nucleus accumbens, SN= substantia nigra.
R
eference
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release might be due to findings that GDNF 
increases TH phosphorylation (Kobori et 
al., 2004�� Salvatore et al., 2004), potentiates 
excitability of cultured midbrain neurons 
by inhibiting transient A-type K+-channels 
(Yang et al., 2001) and, in motor nerve 
terminals, increases Ca2+ influx in evoked 
transmission (Wang et al., 2001). The effects 
of GDNF on dopaminergic systems evoke 
compensatory changes, since long-term 
overexpression of GDNF has been shown to 
downregulate TH expression (Georgievska et 
al., 2004�� Rosenblad et al., 2003) and also 
single intracranial injection of GDNF (100 
µg) decreased striatal TH levels (Salvatore 
et al., 2004). However, long-term striatal 
GDNF overexpression does not affect the 
amount of DAT, VMAT, D1 receptors, D2 
receptors or preproenkephalin expression in 
the striatum (Rosenblad et al., 2003). 
n animal models of Parkinson’s disease, 
GDNF has been shown to protect as well 
as to restore the dopaminergic system from 
drug-induced neurodegeneration. n rats, 
a single GDNF (10 µg) administration or 
prolonged GDNF administration over 4 
weeks (totally 140 µg) to the SN protects 
dopaminergic neurons from nigral or striatal 
6-hydroxydopamine (6-OHDA) lesions 
(Kearns and Gash, 1995�� Sauer et al., 1995). 
n addition, an intrastriatal delivery of 
adenoviral vector encoding human GDNF 
protects rats from striatal 6-OHDA lesion 
(Choi-Lundberg et al., 1997�� Kirik et al., 
2000b). Moreover, a single GDNF (25 µg) 
administration into the striatum is more 
effective in protecting dopaminergic neurons 
from intrastriatal 6-OHDA lesions than 
injection of GDNF into the SN (25 µg) or 
into the lateral ventricle (50 µg), which was 
the least effective (Kirik et al., 2000a). n 
addition, both single administration and 
long-term expression of striatal GDNF 
induces robust sprouting of dopaminergic 
neurons in the striatum (Kirik et al., 2000a�� 
Palfi et al., 2002). The neurorestorative effects 
of GDNF on the dopaminergic system are 
also prominent as GDNF (100 µg) injection 
into the SN of rats restores the dopamine 
content and behavioural consequences of 
medial forebrain bundle 6-OHDA injection 
(Hoffer et al., 1994). Also, GDNF given into 
the SN or striatum protects and restores the 
dopaminergic system in 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP)-treated 
mice (Tomac et al., 1995a). n MPTP-treated 
rhesus monkeys, intraventricular GDNF (300 
µg) restores dopamine function (Gerhardt 
et al., 1999) and lentiviral GDNF delivery 
prevents MPTP-induced neurodegeneration 
and induces increased fluorodopa uptake in 
the striatum (Kordower et al., 2000). The 
outcome from studies done with animal 
models of Parkinson’s disease and also from 
two clinical studies (Gill et al., 2003�� Slevin 
et al., 2005), where GDNF was administered 
into putamen, strongly  indicates that 
GDNF is a potent agent for the treatment of 
Parkinson’s disease. However, there are two 
clinical studies with Parkinsonian patients, 
where GDNF was ineffective. n one study, 
where intraventricular GDNF administration 
was used, GDNF was shown to be ineffective 
(Nutt et al., 2003), but also in a randomized 
controlled clinical study, where intraputamenal 
GDNF administration was used, GDNF was 
shown to be ineffective (Lang et al., 2006). 
2.4. Drug addiction
Drug addiction is a chronic relapsing disorder 
that is characterized by a compulsion to 
seek and take the drug, followed by a loss 
of control over drug intake. Drug craving 
and relapses can occur even after decades 
of abstinence. There are several causes for 
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drug addiction, but factors increasing vul- 
nerability to addiction can be categorized as 
genetic factors, environmental influences and 
drug-induced changes in the brain (Kreek et 
al., 2005). There is a substantial number of 
people who become addicted to illicit drugs 
or alcohol, but repeated drug use does not 
inevitably lead to addiction. Only 15-16% 
of cocaine users become addicted within the 
first 10 years of cocaine use, corresponding 
values for marijuana and alcohol are 8% and 
12-13%, respectively (Wagner and Anthony, 
2002). Studies of genetic epidemiology 
provide evidence that individual differences 
in vulnerability to addiction may have a 
genetic component�� for example genetic 
polymorphisms in the µ-opioid receptor, κ-
opioid receptor, serotonin transporter, D4 
dopamine receptor and COMT gene may 
alter vulnerability to opiate addiction and 
polymorphisms in preprodynorphin, D3 
dopamine receptor, D4 dopamine receptor, 
cannabinoid receptor 1 and dopamine β-
hydroxylase gene to cocaine addiction (for 
review, see Kreek et al., 2005).
The development of drug addiction 
involves a transition phase during which a 
casual use is shifted to compulsive patterns 
of drug use. There are four main theoretical 
explanations for the transition to addiction: 
1. initial drug gives pleasure and subsequent 
withdrawal symptoms lead to development of 
addiction�� 2. addiction is caused by aberrant 
learning in which strong stimulus-response 
habits are developed�� 3. sensitization of neural 
systems causes wanting and motivation to 
take drugs�� 4. normal decision making and 
inhibitory control over behaviour is disturbed 
due to dysfunction of frontal cortical systems 
(Robinson and Berridge, 2003). During 
repeated drug administration, tolerance 
develops to some effects of abused drugs, 
while other effects are sensitized. As discussed 
below, sensitization of dopaminergic systems 
appears to be involved in the development of 
drug addiction.
The traditional view of behavioural 
processes underlying addiction involves 
the term “reinforcement”, which can be 
either positive or negative. The positive 
reinforcement theory assumes that drugs are 
used because of their rewarding effects, and 
positive stimulus increases the probability 
of behaviour leading to the following drug 
use. The negative reinforcement theory of 
addiction assumes that there is a desire to 
use drugs repeatedly in order to suppress 
physical and/or psychological withdrawal 
symptoms and subsequent emergence of 
a negative emotional state when access to 
the drug is prevented (Koob and Le Moal, 
2001). 
Another view of the mechanism of 
drug addiction is that a repeated use of drugs 
can take control of the behaviour. Repeated 
behavioral patterns related to repeated use of 
drug of abuse might lead to compulsive drug 
usage (Gerdeman et al., 2003). n this view, 
a repeated use of abused drugs causes strong 
repetitive and nearly automatic behaviours, 
habits that are centered on the addictive 
substance.
One theory underlying the 
development of addiction is the incentive-
sensitization theory (Robinson and Berridge, 
2003), which proposes that drug-induced 
sensitization of neuronal systems in the brain 
mediate incentive-motivational functions 
that cause drugs to become compulsively 
wanted. There are two different kinds of 
sensitization: 1. psychomotor sensitization 2. 
incentive motivational sensitization, which 
are both thought to be expressed by nucleus 
accumbens-related circuitry. 
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2.4.1. Drug addiction and dopamine
Cerebral dopaminergic systems are of prime 
importance among the neuronal systems 
involved in processing reward information. 
Natural rewards, e.g. food and sex, and most 
drugs of abuse including amphetamine, 
cocaine, opioids, alcohol and nicotine 
increase striatal dopamine release, especially 
in the nucleus accumbens (Di Chiara and 
mperato, 1988�� Wise and Rompre, 1989). n 
addition, when a drug of abuse is associated 
with neutral stimuli, the learning process 
leads to conditioning of accumbal and 
dorsostriatal dopamine release when just the 
neutral stimulus is presented (to et al., 2002). 
However, it has been shown that associative 
learning itself, without reward, is linked to 
enhanced dopamine output in the nucleus 
accumbens but not in the dorsal striatum 
(Young et al., 1998). Schultz and co-workers 
have shown that there is a bursting activity 
of dopamine neurons when a reward occurs 
without prediction, but when the reward 
is predicted by conditioned stimulus the 
bursting activity occurs during the prediction 
and not later when the reward actually occurs 
(Schultz, 1998). Also, when there is a reward 
prediction but no reward, the initial bursting 
activity is seen but dopamine neurons are 
depressed at the time when the reward should 
have occurred. 
During repeated drug administration, 
neuroadaptive processes occur in the 
dopaminergic system. Sensitization of 
the mesolimbic dopaminergic system has 
been proposed to play an important role in 
the development of compulsive drug use 
(Robinson and Berridge, 2003). Withdrawal 
from a repeated drug use can also cause 
depression of the dopaminergic systems which 
might be involved in dysphoria, anxiety and 
depression (Koob and Le Moal, 2001). Taken 
together, these data suggest that dopamine 
is involved in the formation of associations 
between contextual stimuli and rewarding or 
aversive events. 
2.4.2. Sensitization
During repeated administration of abused 
drugs, the behavioural effects can increase 
gradually�� thus, the behavioural responses 
are sensitized in rodents (Ahtee and 
Attila, 1987�� Kalivas and Stewart, 1991�� 
Robinson and Berridge, 2003). n the case 
of psychostimulants, such as cocaine or 
amphetamine, effects on locomotor activity 
can increase dramatically, by three- to four-fold 
as compared with the first dose, or locomotor 
activity may turn into stereotyped behaviour. 
n the case of opioids, the initial sedative or 
cataleptic effects may turn into enhanced 
locomotion and stereotyped behaviour during 
repeated opioid treatment (Ahtee, 1974�� 
Babbini and Davis, 1972). The molecular 
mechanisms underlying sensitization are not 
completely understood, but they are likely to 
include the sensitization of dopamine output, 
alterations in the sensitivity of dopamine 
receptors, alterations in the dopamine uptake 
system or other neurotransmitter systems 
(Robinson and Berridge, 2003). 
There is ample evidence of the 
involvement of dopaminergic systems in 
the sensitization phenomenon (Ahtee and 
Attila, 1987�� Di Chiara, 1995�� Spanagel and 
Weiss, 1999). Alcohol-preferring AA rats, 
which voluntarily consume alcohol, are more 
easily sensitized to repeated morphine and 
cocaine than alcohol non-preferring ANA 
rats, and this phenomenon is accompanied 
by higher brain dopamine output in the AA 
rats (Honkanen et al., 1999�� Mikkola et al.,       
2001�� Mikkola et al., 2002�� Ojanen et al., 
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2003). n addition, withdrawal from repeated     
morphine treatment enhances the sensitivity 
of dopamine D2-like receptor function 
(Piepponen et al., 1996). 
2.4.3. Fos family of immediate early 
genes
Striatal dopaminergic systems are involved 
in the regulation of the fos immediate early 
gene (EG) family (Berretta et al., 1992�� 
Pennypacker et al., 1995). EGs are a set of 
transcription factors that are expressed rapidly 
after cell stimulation. Transcription factors 
encoded by EGs regulate the expression of 
target genes. Regulation of gene expression is 
one mechanism that could underlie the long-
term behavioural changes seen during repeated 
administration of abused drugs (Nestler, 2001). 
Transcription factors of the Fos family form 
complexes with members of the Jun family. 
The heterodimers formed are called activator 
protein-1 (AP-1) complexes, which bind to 
AP-1 sites present in regulatory regions of 
many genes (Morgan and Curran, 1995). 
The most studied EG, c-fos, has been 
used  to characterize of postsynaptic activation 
in different brain areas (Chaudhuri, 1997�� 
Sagar et al., 1988). Acute administration 
of morphine, cocaine, amphetamine and 
nicotine, as well as acute stress or electrical 
stimuli have been shown to induce c-Fos 
rapidly in striatal brain areas (Harlan and 
Garcia, 1998). The expression of c-fos is 
regulated by dopaminergic and glutamatergic 
transmission mainly in the GABAergic 
medium-sized spiny projection neurons in 
striatal brain areas. Dopamine D1 receptors 
mediate c-fos expression in projection neurons 
containing substance P and dynorphin while 
glutamate NMDA-receptors mediate c-fos 
expression in projection neurons expressing 
substance P and dynorphin as well as in 
enkephalin expressing projection neurons 
(Berretta et al., 1992). During repeated 
treatment with drugs of abuse, interesting 
differences have been noted in c-fos expressing 
GABAergic projection neuron cell types. c-Fos 
was present in dynorphin containing neurons 
when the drug was administered in the home 
cage, but when the drug was associated with 
a novel environment, c-Fos was localized in 
both types of GABAergic projection neurons 
(Badiani et al., 1999�� Uslaner et al., 2001). 
 Another Fos-family protein, ∆FosB, 
is accumulated in striatal brain regions after 
chronic administration of abused drugs 
(Nestler et al., 2001). Eric Nestler and co-
workers have extensively studied the role of 
∆FosB in drug addiction as it persists in the 
striatal brain regions after repeated treatment 
with cocaine, morphine and electroconvulsive 
seizures due to its long half-life (Hope et al., 
1994a�� Hope et al., 1994b�� Nye and Nestler, 
1996). The ∆FosB protein is a truncated splice 
variant of full-length FosB, which is encoded 
by the fosb gene. n mice overexpressing 
∆FosB in dynorphin containing GABAergic 
medium-sized spiny projection neurons, the 
rewarding effects of cocaine and cocaine-
induced locomotion were increased (Kelz et 
al., 1999). ∆FosB is also strongly regulated by 
dopaminergic transmission. Dopamine D1 
receptor antagonists attenuate its cocaine-
induced expression (Nye et al., 1995), and in 
D1 receptor knockout mice, repeated cocaine 
administration does not increase ∆FosB levels 
in striatum (Zhang et al., 2002).
2.4.4. Effects of psychostimulants and 
morphine on dopamine
Cocaine and amphetamine are potent 
psychostimulants. Both elevate extracellular 
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dopamine concentrations in the nucleus 
accumbens and in the caudate/putamen by 
acting directly on the nerve terminal (Figure 
2.4.�� Di Chiara and mperato, 1988�� Koob, 
1992). Besides dopaminergic systems, 
cocaine and amphetamine also increase 
neurotransmitter release in noradrenergic 
and serotonergic systems. Cocaine increases 
dopamine release by blocking dopamine 
uptake, and increases the duration of action 
of released dopamine. Cocaine has similar 
effects on noradrenaline and serotonin 
uptake. Surprisingly, the rewarding effect 
of cocaine is not mediated by DAT alone 
as in DAT knockout mice cocaine induces 
place preference (Sora et al., 1998). ndeed, 
it has later been shown that none of these 
transporters alone is crucial for cocaine-
induced reward (Sora et al., 1998�� Uhl et 
al., 2002). Amphetamine affects DAT in a 
different way from cocaine. nside the nerve 
terminal amphetamine acts at synaptic 
vesicles, causing a redistribution of dopamine 
into the cytoplasm, and dopamine is thought 
to be released by reversal in the direction of 
transport mediated by DAT (Sulzer et al., 
1995��Kahlig et al., 2005). 
The effects of opioids are mediated by 
µ-, δ- and κ-opioid receptors. They activate 
brain reward circuitry by dopamine-
dependent and -independent mechanisms 
(Spanagel and Weiss, 1999). Dopamine 
independent mechanisms are relevant as 
dopamine antagonists (Ettenberg et al., 1982�� 
Van Ree and Ramsey, 1987) and destruction 
of dopaminergic nerve terminals in the 
nucleus accumbens (Dworkin et al., 1988�� 
Pettit et al., 1984) have failed to attenuate 
opiate self-administration. Dopamine-
dependent mechanisms are based on the 
ability of opioids to modulate activity of 
ascending dopaminergic neuronal pathways 
in the brain and release of dopamine 
in basal ganglia areas, especially in the 
nucleus accumbens. Direct intraventricular 
administration of µ- or δ- opioid receptor 
agonists increase extracellular dopamine 
concentrations in the nucleus accumbens, 
but κ- opioid receptor agonists decrease it 
(Spanagel et al., 1990). Morphine enhances 
dopamine output by activating µ-opioid 
receptors on GABAergic interneurons 
in the VTA and in the SN (Figure 2.4.). 
The activation of µ-opioid receptors 
disinhibits GABAergic interneurons in the 
VTA and thus leads to enhanced release 
of dopamine (Johnson and North, 1992�� 
Lacey et al., 1989). µ-opioid receptors 
are widely expressed in the CNS. n the 
SNpc, SNpr, VTA and caudate/putamen 
they are localized in the neurites and in 
the nucleus accumbens, ventral pallidum 
and globus pallidus they are localized both 
in the neurites and soma (Mansour et al., 
1995). The effects of morphine on A9 
dopaminergic cells has been shown to depend 
on striatonigral feedback pathways (Gysling 
and Wang, 1983) and direct administration 
of morphine into globus pallidus increases 
accumbal dopamine output (Anagnostakis 
and Spyraki, 1994). Morphine’s effect on 
dopamine output in the nucleus accumbens 
and caudate/putamen is bell-shaped, 
increasing the morphine dose increases 
dopamine output up to certain doses, and 
after that further dose increases reduce the 
dopamine response (Maisonneuve et al., 
2001). The dual effect on striatal dopamine 
release might be indirect and linked to 
findings that intrastriatal administration of 
the µ-opioid receptor agonists morphine 
and DAMGO ([D-Ala2,MePhe4,glycinol5]- 
enkephalin) decreases extracellular striatal 
dopamine levels (Piepponen et al., 
1999). However, accumbal infusions of 
µ-opioid receptor agonists do not alter 
dopamine output (Spanagel et al., 1992), 
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but administration of morphine into 
the ventral pallidum increases accumbal 
dopamine output (Anagnostakis and 
Spyraki, 1994�� Johnson and Napier, 1997). 
Thus, morphine’s effect is inhibitory in 
the dorsostriatal terminal regions and 
stimulatory in the somatodendritic regions, 
ventral pallidum and globus pallidus. 
2.4.5. Neurotrophic factors and drugs of 
abuse
Brain-derived neurotrophic factor (BDNF) 
and GDNF have been shown to be involved 
in adaptations during drug addiction. 
Exogenous GDNF seems to decrease the 
rewarding effects of abused drugs whereas 
exogenous BDNF increases them. However, 
both BDNF and GDNF have been shown 
to block the molecular and cellular changes 
induced by cocaine and morphine. BDNF 
administration into the VTA has been shown 
to block cocaine- or morphine-induced 
increased levels of TH and glial fibrillary acidic 
protein in the VTA (Berhow et al., 1995�� 
Bolanos and Nestler, 2004) and to prevent 
morphine-induced reduction in the cell-body 
and dendrite size of dopaminergic neurons in 
the VTA (Sklair-Tavron et al., 1996). VTA 
injection of GDNF has been shown to block 
morphine- and cocaine-induced increased 
levels of TH and cocaine-induced increase of 
∆FosB and the NMDAR1 glutamate receptor 
Figure 2.4. The mechanisms of action of acute cocaine, amphetamine and opiate drugs on 
mesolimbic dopaminergic neurons. NAc = nucleus accumbens, VP = ventral pallidum, VTA = 
ventral tegmental area, grey neurons represent GABAergic neurons and white neuron represents 
mesolimbic dopaminergic neuron. Cocaine and amphetamine release dopamine by acting directly 
on nerve terminals of dopaminergic neuron, whereas opioids, e.g. morphine increase accumbal 
dopamine release by disinhibiting GABAergic tone that regulates the activity of dopaminergic 
neurons. Figure combined from Anagnostakis and Spyraki, 1994�� Johnson and Napier, 1997�� 
Spanagel and Weiss, 1999. 
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subunit (Messer et al., 2000). n contrast, 
BDNF infusion into the VTA enhances 
locomotor activity and CPP to cocaine 
(Grimm et al., 2003�� Horger et al., 1999�� Lu 
et al., 2004), and in BDNF+/- knockout mice, 
the effects of cocaine are decreased (Hall et al., 
2003�� Horger et al., 1999). Administration 
of GDNF into the VTA has been shown to 
attenuate cocaine-induced place preference 
and to decrease self-administration of cocaine 
and alcohol (Green-Sadan et al., 2003�� Green-
Sadan et al., 2005�� He et al., 2005�� Messer 
et al., 2000), and decreased levels of GDNF 
have been shown to increase rewarding effects 
of cocaine and sucrose (Griffin et al., 2006�� 
Messer et al., 2000). 
Hence, the present hypothesis is that 
increased GDNF levels in the mesolimbic 
system attenuate and decreased levels 
of GDNF augment the molecular and 
behavioural changes induced by abused dugs. 
n addition, drugs of abuse have opposing 
effects on GDNF and BDNF expression, as 
cocaine has been shown to decrease GDNF 
mRNA (Green-Sadan et al., 2003) whereas 
BDNF mRNA expression and protein levels 
are increased by amphetamine, morphine 
and cocaine (Grimm et al., 2003�� Le Foll      
et al., 2005�� Le Foll et al., 2002�� Zhang et 
al., 2002). 
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3. AIMS OF THE STUDY
The discovery of neurotrophic factors has led to studies on their role in the development and 
maintenance of specific neuronal systems. During the past years, there has been increasing 
research to seek novel treatment strategies based on neurotrophic factor signalling in several 
diseases including Parkinson’s disease, but also for other diseases where brain dopaminergic 
systems are affected. The brain dopaminergic systems are involved in the mediation of drug 
reward and functions in the learning process during formation of associations between 
contextual stimuli and rewarding events. Thus, interactions of the neurotrophic factors with 
brain dopaminergic systems are of great interest when studying the role of neurotrophic 
factors in drug addiction. Thus, the specific aims of this study were: 
- To clarify the role of endogenous GDNF in the regulation of striatal dopaminergic 
transmission in heterozygous GDNF knockout mice.
- To study the effects of reduced GDNF levels on cocaine- or morphine-induced striatal 
dopamine release, locomotor stimulatory effects and place conditioning in mice.
- To study the effects of constitutive RET tyrosine kinase receptor activity on the 
dopaminergic system and on the locomotor stimulatory effects of cocaine in mice. Further 
questions asked were how GDNF mediates its effect on dopaminergic neurons via RET, 
and how specific its effects on dopaminergic neurons are.
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4. MATERIALS AND MAIN METHODS 
4.1. Animals
Heterozygous GDNF+/- knockout mice with 
deletion of one allele of the GDNF gene, 
described by Pichel et al. (1996), and their wild-
type littermates were used in studies ,  and 
. Homozygous and heterozygous transgenic 
MEN2B mice and their wild-type littermates 
were used in the study V. This mouse model 
for MEN2B was generated by introducing 
a single point mutation, Met919Thr, 
corresponding to human Met918Thr, into 
the mouse RET gene (Smith-Hicks et al., 
2000). Mice were housed and experiments 
were conducted under standard laboratory 
conditions with controlled temperature 
under a 12:12 h light/dark cycle. The mice 
had free access to mouse chow and water. All 
experiments were approved by the committee 
for Animal Experiments of the University of 
Helsinki or by the chief veterinarian of the 
provincial government. The experiments 
were conducted according to the European 
Convention for the Protection of Vertebrate 
Animals used for Experimental and other 
Scientific Purposes. The mice were genotyped 
from tail DNA by PCR.
Methodological considerations
One way to study the role of GDNF-
GFRα-1/RET signalling in regulation of the 
brain dopaminergic systems is to use gene-
manipulated mouse models, where a gene is 
knocked out or overexpressed, or the function 
of a protein is altered by a mutation. GDNF, 
GFRα-1 and RET homozygous knockout 
mice all express similar phenotypes, and 
homozygous knockout mice die at birth. 
On the other hand, heterozygous mice are 
viable and indistinguisable by eye from 
their wild-type littermates (Enomoto et 
al., 1998�� Moore et al., 1996�� Pichel et al., 
1996�� Sanchez et al., 1996�� Schuchardt et 
al., 1994). Heterozygous GDNF, GFRα-
1 and RET knockout mice can be used 
to study the effects of reduced GDNF-
GFRα-1/RET signalling. The heterozygous 
GDNF knockout mice used in the present 
experiments are by appearance similar to 
their wild-type littermates but about 10% of 
the mice have one kidney smaller than the 
other one. 
GDNF-GFRα-1/RET signalling is 
increased in mice overexpressing GDNF 
in the mesencephalic dopaminergic system 
(Kholodilov et al., 2004). The model for 
increased signalling used in these studies 
is the MEN2B mouse model where a 
point mutation was introduced in the 
endogenous mouse gene encoding RET, 
resulting in a constitutively active receptor. 
Heterozygous MEN2B/+ and homozygous 
MEN2B/MEN2B mice display features of 
the human MEN2B syndrome, including 
C-cell hyperplasia, pheochromocytoma and 
ganglioneuromas (Smith-Hicks et al., 2000). 
Almost all homozygous MEN2B/MEN2B 
mice have C cell hyperplasia at the age of 6-10 
months, but pheochromocytoma is not seen 
in heterozygous mutant mice at any age, nor 
in the homozygous mutants younger than 
3 months. Ganglioneuromas of the adrenal 
glands and sympathetic ganglia are seen only 
in homozygous mutants at all ages. However, 
no abnormalities are seen in the enteric 
nervous system (Smith-Hicks et al., 2000). 
We used mice aged 10 to 12 weeks, when they 
are considered adults but the abnormalities 
are still at minimum. n the MEN2B mice, 
the mutation might lead to altered substrate 
specifity of the RET catalytic domain 
(Santoro et al., 1995�� Songyang et al., 1995), 
and thus, the intracellular signalling might 
be different as compared with that induced 
by GDNF-family ligands. However, to date 
25
no substantial qualitative differences are 
known between the oncogenic and ligand-
activated RET signalling pathways (Sariola 
and Saarma, 2003). 
A major limitation in conventional gene 
manipulated mouse models is that the gene is 
deleted or mutated from the earliest moment 
of embryonic development. When the mice 
are used as adults, the changes observed 
might reflect developmental compensatory 
changes rather than an active role in adult 
plasticity (Chapman, 2002). n the case of 
GDNF-GFRα-1/RET signalling, known to 
be critically important for development, this 
is a relevant limitation. 
4.2. Drugs and treatments
Morphine hydrochloride (studies  & 
, the University Pharmacy, Helsinki, 
Finland), cocaine hydrochloride (studies  
& V�� the University Pharmacy, Helsinki, 
Finland) and d-amphetamine hydrochloride 
(previously unpublished data, the University 
Pharmacy, Helsinki, Finland) were dissolved 
in 0.9% NaCl solution (Sal). Morphine 
and d-amphetamine injections were given 
subcutaneously and cocaine injections were 
given intraperitoneally. The doses refer to 
the base form, and the injection volume of 
10 ml/kg was used. Morphine or cocaine 
was given both acutely and repeatedly. n 
the repeated morphine paradigm, morphine 
30 mg/kg was administered daily on four 
consecutive days, and after 96 h withdrawal, 
a challenge dose (5 or 10 mg/kg) was given. 
n the repeated cocaine administration, 
cocaine was given on consecutive days. n 
the repeated amphetamine experiment, mice 
were given amphetamine 2 mg/kg daily on 
days 1-3, amphetamine 4 mg/kg daily on days 
4-6, and after a six-day withdrawal period, a 
challenge dose of 2 mg/kg was given. 
4.3. Microdialysis in freely moving mice
Detailed descriptions of in vivo microdialysis 
can be found in studies ,  and . Briefly, a 
mouse was anaesthetised and a microdialysis 
guide cannula was aimed at the point above 
the dorsal striatum or the nucleus accumbens. 
Five to seven days after the surgery, at about 
4 p.m., a microdialysis probe was inserted 
into the guide cannula. The microdialysis 
membrane was perfused overnight at low 
perfusion rate with a physiological solution 
closely resembling the cerebrospinal fluid 
but devoid of neurotransmitters and 
their metabolites. n the morning of the 
experimental day, the flow rate was increased 
and the obtained dialysates were separated 
by high performance liquid chromatography 
and concentrations of dopamine, DOPAC, 
HVA and 5-HAA were analyzed by 
an electrochemical detector. After four 
baseline samples, the drug to be studied 
was administered. Samples were collected 
continuously every 20 min. The effects 
of drugs are presented as relative to the 
baseline (= the average concentration of 
four consecutive stable samples defined as 
100%). The experiments with the MEN2B 
mice were conducted similarly, but different 
probes were used (MAB4, Agn Tho’s AB, 
Lidingö, Sweden).
Methodological considerations
Microdialysis mimics the function of a small 
blood vessel. t is used for exploring the 
chemistry of a tissue at the extracellular level 
(Ungerstedt, 1991). With a semi-permeable 
membrane, substances can be withdrawn 
from and delivered to a tissue where the probe 
has been inserted. n neuropharmacological 
research microdialysis is commonly 
used for studying the effects of different 
treatments on extracellular neurotransmitter 
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concentrations in different brain regions of 
laboratory animals. The main advantages of 
in vivo microdialysis, as used in the present 
experiments, are the use of awake and freely 
moving mice and continuous monitoring 
of the concentrations of dopamine and 
its metabolites over a long time. Also, as 
the stabilization time is long, the basal 
concentrations are stable. The probes used 
in the experiment have low recovery, about 
5% (CMA/7), and thus, the removal of 
dopamine and its metabolites minimally 
interferes with physiological dopamine 
turnover. The main disadvantages are the 
relatively large size of the microdialysis 
probe (o.d. 240 µm) and that insertion of 
the probe causes damage to the tissue. n 
addition, with microdialysis a relatively poor 
time resolution can be achieved (20 min). 
4.4. Cerebral monoamine analysis from 
tissue samples 
Detailed descriptions of monoamine analysis 
can be found in studies  and V. Briefly, in 
study , mice were given saline or morphine 
5, 10 or 30 mg/kg s.c. one hour before 
the mice were killed by decapitation. The 
brains were rapidly excised, dissected and 
stored at -80°C until assay. Monoamines 
and their metabolites were detected using an 
ESA® CoulArray Electrode Array Detector 
and chromatograms were processed and 
concentrations of monoamines calculated 
using CoulArray® software. Monoamine 
and metabolite values were calculated as 
nanograms per gram (ng/g) wet weight of 
the tissue.
Methodological considerations
Monoamine analysis from tissue samples is a 
technique to study the chemistry of a tissue 
on the intracellular level. ts limitations are 
mainly related to the dissection technique, 
and the dissection method might cause 
variability and bias to the analysed brain 
region. Dissection can be performed either 
by punching or by pinching from a brain 
section containing the structures of interest. 
Punching can be used to collect dorsal and 
ventral striatum separately, whereas pinching 
with forceps can be used to collect the entire 
striatum. n study V, the SN/VTA was 
punched, and it is to be noted, that the tissue 
taken did not cover those brain nuclei totally, 
but only partially. 
4.5. Locomotor activity monitoring 
A detailed description of the method 
used can be found in studies ,  and V. 
Briefly, locomotor activity was monitored 
in transparent plastic cages. The movement 
of the mice caused interruptions of infrared 
photobeams, and these were recorded by 
a computer and afterwards analyzed. The 
mice were habituated to the test boxes in 
all other experiments but not in the novelty 
seeking experiment of the MEN2B mice 
(study V). 
Methodological considerations
Locomotor activity can be used to study 
the effects of different drug treatments 
or the effects of gene manipulations on 
motor behaviour. Neurotransmitters, such 
as dopamine, noradrenaline and excitatory 
amino acids have been shown to be 
involved in locomotor activity. Behavioural 
sensitization has been defined as drug-
induced enhancement of locomotor activity 
responses following repeated injections of a 
drug, and it has been observed with most 
abused drugs. 
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4.6. Place conditioning 
A detailed description of the method 
used can be found in study . Briefly, 
the tests were conducted in standard 
conditioned place preference (CPP) 
boxes. CPP trials were divided into three 
stages: 1. Habituation & preconditioning 
2. Conditioning 3. Postconditioning. A 
temporal interval of 10 min was used in 
the pre- and postconditioning tests. About 
half of the animals were conditioned in 
the side where they spent less time, while 
the other half were conditioned in the side 
where they spent more time, to be paired 
with morphine. n the mornings, the mice 
were given saline and assigned to the saline-
paired compartment for 60 min. Three 
to four hours later, the mice were given 
morphine or saline and assigned to the drug-
paired compartment for 60 min. Different 
protocols were used in morphine 5 mg/kg 
and 10 mg/kg experiments, as the aim was 
to study both the development and duration 
of the place preference (Table 4.1.).
Methodological considerations
The CPP paradigm has proven to be a 
useful tool in the investigation of rewarding 
properties of drugs (Hoffman, 1989). CPP 
reflects a preference for a context due to the 
contiguous association between the context 
and a drug stimulus. n CPP experiments, 
morphine causes incentive learning, eliciting 
drug-seeking behaviour that is believed to 
be mediated by nucleus accumbens -related 
reward circuitry (Bardo and Bevins, 2000�� 
Spanagel and Weiss, 1999�� Tzschentke, 
1998). n the present experiments, CPP 
testing was done accordingly to criteria 
of unbiased principles. The mice were 
conditioned about equally to the side where 
they preferentially spent less time and to 
the side where they spent more time. n the 
biased method, all mice are conditioned 
to the side where they spent preferentially 
less time, but this protocol is subject to 
interference from the potential antianxiety 
effect of the test drug. 
Table 4.1. Time schedules of CPP experiments.
Morphine 5 mg/kg Morphine 10 mg/kg
Day 1 Habituation Habituation
Day 2 Habituation Habituation
Day 3 Preconditioning test Preconditioning test
Day 4 Conditioning Conditioning 
Day 5 Conditioning Conditioning 
Day 6 Postconditioning test Conditioning
Day 7 Conditioning Conditioning
Day 8 Conditioning Postconditioning test
Day 9 Postconditioning test
Day 15 Postconditioning test
Day 22 Postconditioning test
Day 29 Postconditioning test
Day 44 Postconditioning test
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4.7. Immunological methods
mmunohistochemistry was done as described 
in studies  and V. Briefly, the mice were 
anaesthetized and perfused intracardially 
with phosphate-buffered saline followed 
by 4% paraformaldehyde. The brains were 
removed, postfixed for 4 h and stored in 
sodium phosphate buffer containing 20% 
sucrose at 4°C. Coronal sections (30-40 
µm) were cut on a cryostat (Leica CM 
3050, Leica Microsystems Nussloch GmbH, 
Nussloch, Germany) throughout the 
brain. Free-floating sections from selected 
brain regions were stained using standard 
immunohistochemical procedures. n study 
, polyclonal rabbit antibody to FosB (H-
75, sc-7203, Santa Cruz Biotechnology nc., 
CA, USA) was used. n study V, polyclonal 
rabbit antibody to TH (Chemicon, AB152) 
and monoclonal rat antibody to the DAT 
(Chemicon, MAB 369) was used. n 
experiments with c-Fos polyclonal rabbit 
antibody (PC38, Calbiochem) was used. The 
stained sections were mounted on gelatin/
chrome-alume coated slides and coverslipped 
with DePex. The atlas of Franklin and 
Paxinos (1997) was used to identify different 
brain regions. mmunostained nuclei and 
cells were quantified with a computerized 
image-analysis system including a camera, 
a microscope and a computer with either 
mage-Pro Plus 4.0 or Stereonvestigator 
software. The countings were conducted 
so that the observers were blinded to the 
experimental design. 
GDNF concentrations were analyzed 
from heterozygous GDNF+/- mice by 
ELSA-assay as described in study . Briefly, 
dorsal and ventral striatum were dissected 
and frozen into microcentrifuge tubes on 
dry ice to minimize condensation and 
frozen and stored at -80°C. Tissues were 
homogenized in 400 µl of lysis buffer 
(TBS, 1% NP40, 10% glycerol, Complete 
Protease nhibitor Cocktail tablet, Roche 
Diagnostics, Basel, Switzerland). GDNF 
concentrations were measured using GDNF 
E
max
® immunoassay system (Promega, W, 
USA), strictly following the manufacturer’s 
instructions. For each GDNF measurement, 
tissues from 8-9 mice were pooled, and the 
results presented are means (± SEM) of three 
separate measurements.
Methodological considerations
mmunological methods are useful in 
locating and quantifying proteins. They are 
based on exquisite specificity of antibodies 
for their target proteins. Antibodies can be 
either monoclonal or polyclonal. Polyclonal 
antibodies are heterogeneous mixtures of 
antibodies, each specific for one of the 
various epitopes of the antigen. Monoclonal 
antibodies are produced by a single antibody-
producing cell clone and they recognize a 
specific epitope. n the present experiments, 
antibodies to FosB, c-Fos and TH were 
polyclonal and the antibody to DAT was 
monoclonal. The FosB antibody recognizes 
both the FosB and ∆FosB isoforms. The 
main limitations in using immunological 
methods are the detection methods of the 
immunostained proteins, which usually are 
semi-quantitative. n ELSA experiments 
a limitation is the dissection accuracy, and 
when analyzed immunostained brain sections 
a question is whether the whole region of 
interest is systematically analyzed or only 
parts of it.  
4.8. Statistics
Locomotor activity data were analyzed by one- 
or two-way analysis of variance (ANOVA) for 
repeated measurements. The CPP data were 
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analyzed by two-way ANOVA and by paired 
t-test. Microdialysis data were analyzed 
by one- or two-way ANOVA for repeated 
measurements and further analyses were 
conducted with Tukey/Kramer post hoc test. 
Basal dopamine, DOPAC, HVA, 5-HAA 
and GDNF concentration data were analyzed 
by Student’s t-test. mmunohistochemistry 
data were analyzed by one-way ANOVA 
and Student’s t-test. All results are given as 
mean ±SEM, and the results were considered 
statistically significant at P<0.05. 
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5. RESULTS 
5.1 Striatal GDNF concentrations in 
GDNF+/- mice and in their wild-type 
littermates (I)
Tissue GDNF concentration in the dorsal 
striatum was 8.9±0.7 pg/mg tissue in the 
Wt mice and 5.0±0.5 pg/mg tissue in the 
GDNF+/- mice. The GDNF concentrations 
were significantly reduced in the GDNF+/-
mice by 44% (P=0.009, Student’s t-test). n 
the ventral striatum GDNF concentration 
in the Wt mice was 5.4±0.4 and in the 
GDNF+/- mice 4.4±0.3. The difference 
(18%) was not  significant (P=0.085). 
5.2. Effects of depletion of one GDNF 
allele on the brain dopaminergic system 
and on basal locomotor activity (I, II)
As summarized in Table 5.1, there were no 
significant differences in the post-mortem 
tissue concentrations of striatal dopamine, 
DOPAC and HVA between the Wt and 
the GDNF+/- mice (dopamine: P=0.0759�� 
DOPAC: P=0.3648�� HVA: P=0.3284, 
Student’s t-test).
As summarized in Table 5.1, the 
steady-state extracellular concentration 
of dopamine was higher in the dialysates 
of the caudate putamen and the nucleus 
accumbens of the GDNF+/- mice than 
in those of the Wt mice. The increase was 
2.0-fold in the caudate putamen (P<0.001, 
Student’s t-test) and 1.6-fold in the nucleus 
accumbens (P=0.017, Student’s t-test). 
There were no significant differences 
between DOPAC and HVA concentrations 
in the caudate putamen or in the nucleus 
accumbens perfusates between GDNF+/- 
and Wt mice. 
As summarized in Table 5.1, the 
cumulative ambulatory counts in the 24-h 
locomotor activity assessment were similar. 
5.3. c-Fos and FosB/∆FosB immunostain-
ing in GDNF+/- mice and in their wild-
type littermates (I, unpublished)
As summarized in Table 5.2, the number of 
FosB immunostained nuclei was clearly higher 
in the striatal brain regions in the GDNF+/- 
mice than in the Wt mice. The elevation 
was 2.2-fold in the nucleus accumbens core 
area (P=0.044, Student’s t-test), 1.6-fold in 
the nucleus accumbens shell area (P=0.04, 
Student’s t-test), and 5.7-fold in the caudate 
putamen (P=0.026, Student’s t-test). n the 
cingulate cortex, there was no statistically 
significant difference in the number of 
FosB immunostained nuclei between the 
GDNF+/- and Wt mice (P=0.077, Student’s 
t-test, unpublished data). Similarly, the 
number of c-Fos immunostained nuclei 
was increased in the caudate putamen and 
cingulated cortex in the GDNF+/- mice 
(P=0.045, P=0.031, respectively, Student’s t-
test, unpublished data). 
5.4. Effects of acute and repeated cocaine 
in GDNF+/- mice and in their wild-type 
littermates (I) 
As summarized in Table 5.3, the locomotor 
activities after acute saline did not differ 
between the GDNF+/- and Wt mice. Acute 
cocaine, 10 mg/kg, stimulated locomotor 
activity in the mice of both genotypes 
(treatment effect: P<0.0001, genotype 
X treatment interaction: P=0.8276, 
ANOVA). The stimulatory effect of cocaine 
on locomotor activity was gradually and 
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significantly increased from the first dose to 
the fourth dose and locomotor sensitization to 
cocaine developed similarly in the GDNF+/- 
and Wt mice (day effect: P<0.0001, day X 
genotype interaction: P=0.911, ANOVA for 
repeated measurements).
The effects of acute cocaine, 10 mg/
kg, on accumbal dopamine output were 
similar in the GDNF+/- and Wt mice, 
when the dopamine output was calculated 
as percentage from the baseline. After pre-
treatment with cocaine 10 mg/kg daily 
on three consecutive days, the response to 
cocaine on the fourth day was decreased in 
the GDNF+/- mice. There was a significant 
difference between the Wt and GDNF+/- 
mice (ANOVA for repeated measures, 100-
160 min, P=0.046). After pre-treatment with 
cocaine, the difference in baseline dopamine 
concentrations between the GDNF+/- and 
Wt mice was only 14%. 
5.5. Effects of repeated amphetamine 
treatment on locomotor activity in 
GDNF+/- mice and in their wild-type 
littermates (unpublished). 
As shown in Figure 5.1, locomotor activities 
after amphetamine 2 mg/kg (s.c.) injections 
were similar in the GDNF+/- and Wt mice. 
During the first three days, there were similar 
daily increases in amphetamine-enhanced 
locomotion in both genotypes (genotype 
effect: P=0.3360, day effect: P=0.0217, day 
X genotype interaction: P=0.9074, ANOVA 
for repeated measures). After withdrawal, 
Tissue concentrations (ng/g) n=23-24
Brain area and 
genotype
Dopamine DOPAC HVA
CPu
Wt 12700 ± 50 1020 ± 70 750 ± 50
GDNF+/- 11500 ± 40 930 ± 60 680 ± 50
%-difference ↔ ↔ ↔
Extracellular concentrations n=12-26
Brain area and 
genotype
Dopamine (nM) DOPAC (µM) HVA (µM)
CPu n=12-15
Wt 0.31 ± 0.04 0.13 ± 0.02 0.13 ± 0.02
GDNF+/- 0.63 ± 0.07 *** 0.15 ± 0.01 0.15 ± 0.02
%-difference ↑↑ ↔ ↔
NAc (n=24-26)
Wt 0.37 ± 0.04 0.10 ± 0.01 0.07 ± 0.01
GDNF+/- 0.60 ± 0.08 * 0.12 ± 0.01 0.08 ± 0.01
%-difference ↑ ↔ ↔
 
24-h locomotor activity (cumulative ambulatory counts, n=11-12)
Wt 3130±280
GDNF+/- 2850±270
Table 5.1. Dopamine, DOPAC, and HVA concentrations in the post mortem striatal tissues and 
in the steady-state microdialysis samples in the GDNF+/- and Wt mice. ↔ indicates that the 
difference between GDNF+/- and Wt mice is less than 30%, ↑ indicates 50-70% increase, ↑↑ 
indicates 80-110% increase, * P<0.05, ***P<0.001.
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there was similar and robust locomotor 
sensitization in the Wt and GDNF+/- mice 
(day effect between days 3 and 12: P=0.0001�� 
genotype effect: P=0.8969�� day X genotype 
interaction: P=0.6625).
5.6. Effects of acute and repeated morphine 
on locomotor behaviour in GDNF+/- mice 
and in their wild-type littermates (III)
When a large dose of morphine (30 mg/kg 
s.c.) was given daily on four consecutive days, 
there was a difference between the genotypes 
in distance travelled on day 4. The first dose of 
morphine increased distances travelled by the 
Wt and GDNF+/- mice similarly. However, 
after the fourth daily morphine dose the 
GDNF+/- mice travelled less than on day 1 
Brain region 
and genotype FosB/∆FosB c-Fos
CPu 
Wt 9 ± 3 7 ± 2
GDNF+/- 49 ± 13 42 ± 13
%-difference ↑↑↑↑ * ↑↑↑↑ *
NAcC
Wt 105 ± 24 34 ± 10
GDNF+/- 230 ± 37 62 ± 16
%-difference ↑↑ * ↑
NAcSh
Wt 228 ± 16 73 ± 9
GDNF+/- 365 ± 47 111 ± 26
%-difference ↑  * ↑
CG
Wt 29± 5 40 ± 12
GDNF+/- 54± 9 100 ± 17
%-difference ↑ ↑↑↑  *
Table 5.2. Number of FosB/∆FosB and 
c-Fos immunostained nuclei in caudate 
putamen (CPu), nucleus accumbens core 
(NAcC), nucleus accumbens shell (NAcSh) 
and in the cingulate cortex (CG) of the 
GDNF+/- and Wt mice. ↑ indicates 50-90% 
increase, ↑↑ indicates 100-130% increase, 
↑↑↑ indicates 140-170% increase, ↑↑↑↑ 
indicates 440-500% increase  * P<0.05 as 
compared with the Wt mice.
(time 60-120 min, P=0.0458, ANOVA for 
repeated measures), whereas the distances 
travelled by the Wt mice were similar after the 
first and the fourth doses (n=28-40). 
The effects of acute morphine (5 and 
10 mg/kg) were similar on locomotor activity 
in the Wt and GDNF+/- mice. However, 
after 96 h withdrawal from the fourth daily 
injection of morphine (30 mg/kg), the 
morphine challenge dose 5 mg/kg stimulated 
locomotor activity in the GDNF+/- mice, 
but no such stimulation occurred in 
correspondingly treated Wt mice. At 15-65 
min after administration of the challenge 
dose, the distance travelled by the morphine 
pretreated GDNF+/- mice was significantly 
longer than that of the Wt mice (P=0.024, 
ANOVA for repeated measures). However, 
the responses to the morphine 10 mg/kg 
challenge dose were robustly and similarly 
sensitized in mice of both genotypes after 
96 h withdrawal from the 4-day morphine 
pre-treatment. The distances travelled were 
significantly longer (5-8-fold) in morphine 
pretreated than in saline pretreated mice 
(pretreatment effect 15-120 min: P=0.0002, 
ANOVA for repeated measures). When both 
the morphine challenge doses were analyzed 
together, there was a tendency for genotype 
X treatment interaction (P=0.0898), and a 
statistically significant time X genotype X 
treatment  interaction was found (P=0.0315, 
time 20-60 min).
5.7. Effects of acute morphine on striatal 
tissue dopamine, DOPAC and HVA 
concentrations in GDNF+/- mice and in 
their wild-type littermates (II)
Acute morphine administration did not alter 
striatal tissue dopamine concentrations in 
mice of either genotype (treatment effect: 
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P=0.0791�� treatment X genotype interaction: 
P=0.4061, ANOVA). As summarized in Table 
5.4, morphine increased striatal DOPAC 
in the Wt and GDNF+/- mice (treatment 
effect Wt: P<0.0001�� GDNF+/-: P=0.001, 
genotype X treatment interaction: P=0.1922) 
and HVA in the Wt mice (treatment effect 
P=0.0192) but not in the GDNF+/- mice 
(treatment effect: P=0.1281�� genotype X 
treatment interaction: P=0.4461). Morphine 
Locomotor activity 
Saline day 1 Cocaine day 2 Cocaine day 5
Wt 1750±290 cm 2.9-fold 8.9-fold
GDNF+/- 1720±370 cm 3.2-fold 9.7-fold
Dopamine concentrations nM
Baseline in saline 
pre-treated
Maximal concentration 
of cocaine-induced 
output in saline 
pre-treated
Baseline in cocaine 
pre-treated
Maximal concentration 
of cocaine-induced 
output in cocaine 
pre-treated 
Wt 0.48 ± 0.10 1.18 ± 0.37 ↑↑ 0.47 ± 0.08 1.49 ± 0.39 ↑↑↑
GDNF+/- 0.67 ± 0.19 1.61 ± 0.45 ↑↑ 0.54 ± 0.16 1.20 ± 0.40 ↑↑
Table 5.3. The effects of acute (day 2) and repeated cocaine (day  5) on locomotor activity and 
on accumbal dopamine concentrations. n locomotor activity the fold-change is calculated from 
the corresponding saline (day 1) treatment. n the lower panel, the maximal dopamine output 
is from the time point 120 min after cocaine administration (Study ). ↑↑ indicates 120-150% 
increase, ↑↑↑ indicates that the increase is 210-220%. 
Figure 5.1. The effect of amphetamine 
2 mg/kg on locomotor activity. The mice 
were given amphetamine 2 mg/kg s.c. on 
days 1-3, amphetamine 4 mg/kg on days 
4-6 and six days after withdrawal, on day 
12, the mice were given a challenge dose of 
amphetamine 2 mg/kg, n=12.
5 mg/kg did not have effect on DOPAC or 
HVA concentrations, morphine 10 mg/kg 
elevated DOPAC significantly only in the 
GDNF+/- mice and morphine 30 mg/kg 
elevated DOPAC both in the GDNF+/- 
and Wt mice (P<0.05, Tukey/Kramer post 
hoc test). Morphine 30 mg/kg elevated the 
metabolites more in the Wt mice (DOPAC: 
66%, HVA 35%) than in the GDNF+/- mice 
(DOPAC: 45%, HVA 23%), when just the 
effects of morphine 30 mg/kg were analyzed 
there was a statistically significant genotype 
effect on DOPAC (P=0.0203) and on HVA 
(P=0.0421).
5.8. Effects of acute and repeated morphine 
on accumbal dopamine, DOPAC and HVA 
output in GDNF+/- mice and in their 
wild-type littermates (II, III)
Baseline dopamine, DOPAC and HVA 
concentrations in morphine-withdrawn mice
As shown in Table 5.5, repeated morphine 
treatment reduced the basal extracellular 
dopamine concentrations in the GDNF+/- 
mice but did not alter those in the Wt mice. 
n morphine-naive GDNF+/- mice the 
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extracellular dopamine concentration in 
the nucleus accumbens was 1.6-fold higher 
than in the Wt mice. However, there were 
no differences in the steady-state accumbal 
extracellular dopamine concentrations 
Morphine 5 Morphine 10 Morphine 30
DOPAC
Wt 900±60  ↔ 1230±100 ↑ 1690±130 ↑↑↑ *
GDNF+/- 1020±70 ↔ 1170±70 ↑ * 1350±80 ↑↑ * °
HVA
Wt 670±80 ↔ 790±60 ↔ 1010±70   ↑↑
GDNF+/- 710±70 ↔ 810±40 ↔ 840±70   ↑ °
Table 5.4. Tissue DOPAC and HVA (ng/g) concentrations in morphine-treated (5, 10 and 
30 mg/kg) Wt and GDNF+/- mice as compared with saline treatment. n saline-treated mice 
DOPAC concentrations were 1020±70 (Wt) and 930±60 (GDNF+/-) and HVA concentrations 
were 750±50 (Wt) and 680±50 (GDNF+/-). ↑ indicates increase of 20-30 %, ↑↑ indicates 
increase of 30-60%, ↑↑↑ indicates increase of 60% or more, ↔ indicates that the difference 
is less than 20%, * indicates P<0.05 as compared with the corresponding saline treatment, ° 
indicates P<0.05 as compared with corresponding Wt mice, Tukey/Kramer post hoc test. 
Acute Mo5 Acute Mo10 Challenge Mo5 Challenge Mo10
Baseline  
concentra-
tion
Concentra-
tion at 120 
min after 
injection
Baseline  
concentra-
tion
Concentra-
tion at 120 
min after 
injection
Baseline  
concentra-
tion
Concentra-
tionat 120 
min after 
injection
Baseline  
concentra-
tion
Concentra-
tion at 120 
min after 
injection
Dopamine (nM)
Wt 0.36±0.06  0.51±0.13 
↑ *
0.37±0.11 0.58±0.14 
↑↑ * °    
0.41±0.09 0.49±0.11 
↑ *    
0.43±0.18 0.74±0.21 
↑↑↑  * °   
GDNF+/- 0.64±0.15 1.16±0.22 
 ↑↑↑ * #  
0.56±0.16 0.76±0.24 
↑↑ * °    
0.42±0.09 0.63±0.15 
↑↑ * #  
0.45±0.12 0.63±0.16 
↑ *     
DOPAC  (µM)
Wt 0.11±0.02 0.08±0.01 
↔       
0.11±0.03 0.17±0.05 
↑↑ * °    
0.11±0.02 0.14±0.02 
↑ *     
0.15±0.04 0.23±0.04 
↑↑ * °  
GDNF+/- 0.11±0.02 0.15±0.02 
↑ *   
0.13±0.04 0.16±0.02 
↑ *       
0.12±0.02 0.16±0.01
↑ *     
0.08±0.01 0.12±0.02 
↑↑ * °  
HVA (µM)
Wt 0.07±0.01 0.09±0.01 
↑ *      
0.07±0.02 0.10±0.03 
↑↑ * °    
0.10±0.01 0.14±0.02
↑ *     
0.12±0.02 0.18±0.02 
↑↑ *     
GDNF+/- 0.08±0.01 0.11±0.02 
↑ *      
0.09±0.02 0.11±0.02 
↑ *       
0.10±0.01 0.14±0.01
↑ *     
0.07±0.02 0.10±0.02 
↑↑ *     
Table 5.5. The effects of acute and challenge morphine (Mo) on dopamine, DOPAC and HVA 
output in the nucleus accumbens. The arrows indicate the effect of morphine at 120 min after the 
injection as compared with the baseline. The baseline values for each group are given in brackets. 
↑ indicates increase of 20-40 %, ↑↑ indicates increase of 41-70%, ↑↑↑ indicates increase of 
71-100%, ↔ indicates less than 20% increase, * indicates P<0.05 as compared with the saline 
treatment, ° indicates P<0.05 as compared with effect of morphine 5 mg/kg, # indicates P<0.05 
as compared with the corresponding Wt mice. 
between the Wt and GDNF+/- mice 
withdrawn 96 h from 4 day morphine 
treatment (GDNF+/-: 0.43±0.07 nM, Wt: 
0.41±0.09 nM, P=0.8961, Student’s t-test, 
n=13). Neither were there any differences in 
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Acute Mo5 Acute Mo10 Challenge Mo5 Challenge Mo10
Baseline  
concentra-
tion
Concentra-
tion at 120 
min after 
injection
Baseline  
concentra-
tion
Concentra-
tion at 120 
min after 
injection
Baseline  
concentra-
tion
Concentra-
tionat 120 
min after 
injection
Baseline  
concentra-
tion
Concentra-
tion at 120 
min after 
injection
Dopamine (nM)
Wt 0.36±0.06  0.51±0.13 
↑ *
0.37±0.11 0.58±0.14 
↑↑ * °    
0.41±0.09 0.49±0.11 
↑ *    
0.43±0.18 0.74±0.21 
↑↑↑  * °   
GDNF+/- 0.64±0.15 1.16±0.22 
 ↑↑↑ * #  
0.56±0.16 0.76±0.24 
↑↑ * °    
0.42±0.09 0.63±0.15 
↑↑ * #  
0.45±0.12 0.63±0.16 
↑ *     
DOPAC  (µM)
Wt 0.11±0.02 0.08±0.01 
↔       
0.11±0.03 0.17±0.05 
↑↑ * °    
0.11±0.02 0.14±0.02 
↑ *     
0.15±0.04 0.23±0.04 
↑↑ * °  
GDNF+/- 0.11±0.02 0.15±0.02 
↑ *   
0.13±0.04 0.16±0.02 
↑ *       
0.12±0.02 0.16±0.01
↑ *     
0.08±0.01 0.12±0.02 
↑↑ * °  
HVA (µM)
Wt 0.07±0.01 0.09±0.01 
↑ *      
0.07±0.02 0.10±0.03 
↑↑ * °    
0.10±0.01 0.14±0.02
↑ *     
0.12±0.02 0.18±0.02 
↑↑ *     
GDNF+/- 0.08±0.01 0.11±0.02 
↑ *      
0.09±0.02 0.11±0.02 
↑ *       
0.10±0.01 0.14±0.01
↑ *     
0.07±0.02 0.10±0.02 
↑↑ *     
Table 5.5. The effects of acute and challenge morphine (Mo) on dopamine, DOPAC and HVA 
output in the nucleus accumbens. The arrows indicate the effect of morphine at 120 min after the 
injection as compared with the baseline. The baseline values for each group are given in brackets. 
↑ indicates increase of 20-40 %, ↑↑ indicates increase of 41-70%, ↑↑↑ indicates increase of 
71-100%, ↔ indicates less than 20% increase, * indicates P<0.05 as compared with the saline 
treatment, ° indicates P<0.05 as compared with effect of morphine 5 mg/kg, # indicates P<0.05 
as compared with the corresponding Wt mice. 
for repeated measures, P=0.0228, P<0.05 
between saline & morphine 10 mg/kg and 
morphine 5 mg/kg & morphine 10 mg/kg�� 
Tukey/Kramer post hoc test). However, in 
the GDNF+/- mice, both morphine doses 
(5 & 10 mg/kg) increased DOPAC output 
(P=0.0449, P<0.05 between saline & 
morphine 5 mg/kg and saline & morphine 
10 mg/kg, morphine 5 mg/kg and morphine 
10mg/kg�� Tukey/Kramer post hoc test). 
Morphine increased HVA output statistically 
significantly in the mice of both genotypes 
(treatment effect: P=0.0042, treatment X 
genotype interaction: P=0.9252, 100-320 
min, ANOVA for repeated measures). n 
the Wt mice, this effect was dose-dependent 
(P<0.05 Tukey/Kramer post hoc test), but in 
the GDNF+/- mice both morphine doses 
(5 and 10 mg/kg) increased HVA output 
similarly. 
Effects of morphine challenge on accumbal 
dopamine, DOPAC and HVA output in 
morphine-withdrawn mice
As summarized in Table 5.5, 96 h after 
withdrawal from repeated morphine 
treatment, challenge doses of morphine 
increased the accumbal dopamine output in 
both the Wt and GDNF+/- mice (ANOVA for 
repeated measures, P=0.0048). nterestingly, 
there was a highly significant difference at 
the time 100-320 min (time X genotype X 
treatment interaction: P=0.0159) showing 
that the time-response curves of morphine 
differ between the mice of the two genotypes. 
When just the effects of morphine 5 mg/
kg were analyzed, morphine was found to 
significantly increase dopamine output more 
in the GDNF+/- mice than in the Wt mice 
(ANOVA for repeated measures, genotype 
effect at 180-260 min: P=0.0329). n addition, 
the effect of morphine was dose-dependent 
in the Wt mice (treatment effect at 100-260 
min: P=0.0140, P<0.05 between saline & 
DOPAC (GDNF+/-: 0.11±0.014 µM, Wt: 
0.13±0.017 µM, P=0.3170, Student’s t-test, 
n=13) or HVA (GDNF+/-: 0.089±0.003 µM, 
Wt: 0.109±0.011 µM, P=0.1803, Student’s 
t-test, n=13) concentrations between the Wt 
and GDNF+/- mice withdrawn 96 h from 4 
day morphine treatment. 
Effects of acute morphine on accumbal 
dopamine, DOPAC and HVA output
As summarized in Table 5.5, acute 
morphine elevated accumbal dopamine 
output differently in the GDNF+/- and 
Wt mice (treatment effect: P=0.0167, 
treatment X genotype interaction: P=0.0699, 
treatment X genotype X time 20-320 min 
interaction: P<0.0001). Acute morphine 
dose-dependently increased the accumbal 
dopamine output in the Wt mice (ANOVA 
for repeated measures P=0.0379, P<0.05 
between saline& morphine 5 mg/kg, saline & 
morphine 10 mg/kg and morphine 5 mg/kg 
& morphine 10 mg/kg�� Tukey/Kramer post 
hoc test). n the GDNF+/- mice, morphine 
5 mg/kg increased the accumbal dopamine 
levels robustly and clearly more than the 
dose of 10 mg/kg (ANOVA for repeated 
measures P=0.0232, P<0.05 between saline 
& morphine 5 mg/kg, saline & morphine 10 
mg/kg and morphine 5 mg/kg & morphine 
10 mg/kg�� Tukey/Kramer post hoc test) 
or than the 5 mg/kg dose in the Wt mice 
(genotype effect: P=0.0359). Morphine 10 
mg/kg -induced increases were similar in 
both genotypes�� about 80% in the Wt mice 
and about 60% in the GDNF+/- mice. 
As summarized in Table 5.5, the 
effect of morphine on DOPAC output 
differs significantly between the genotypes 
(genotype X treatment interaction 100-
320 min: P=0.0287). n the Wt mice, acute 
morphine increased the accumbal DOPAC 
output only at the dose of 10 mg/kg (ANOVA 
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morphine 5 mg/kg, saline & morphine 10 
mg/kg and morphine 5mg/kg & morphine 
10 mg/kg�� Tukey/Kramer post hoc test), but 
in the GDNF+/- mice morphine 5 and 10 
mg/kg increased dopamine output similarly 
(treatment effect at 100-260 min: P=0.0469�� 
P<0.05 between saline & morphine 5 mg/kg 
and saline & morphine 10 mg/kg, Tukey/
Kramer post hoc test). 
Challenge doses of morphine similarly 
and dose-dependently increased the accumbal 
DOPAC output in the Wt and GDNF+/- 
mice (treatment effect: P=0.0013, X genotype 
interaction: P=0.7443, 140-320min, P<0.05 
between saline & morphine 5 mg/kg, saline 
& morphine 10 mg/kg, morphine 5 mg/kg 
& morphine 10 mg/kg�� Tukey/Kramer post 
hoc test). Both challenge doses of morphine 
increased the accumbal HVA output similarly 
in the Wt and GDNF+/- mice (treatment 
effect: P<0.0001, treatment X genotype 
interaction: P=0.7066, 140-320min).
5.9. Effects of morphine on CPP behaviour 
in GDNF+/- mice and in their wild-type 
littermates (III)
The effects of morphine 5 mg/kg on 
CPP are summarized in Table 5.6. The 
preconditioning times (s±SEM) before 
morphine 5 mg/kg or saline treatments 
were similar in the Wt and GDNF+/- mice 
(Wt saline: 301±16�� Wt mo5: 282±13�� 
GDNF+/- saline: 327±23�� GDNF+/- mo5: 
316±25). On day 6, after two conditioning 
sessions, place preference to morphine 5mg/
kg or saline had not developed in either 
genotype. After four conditioning sessions 
on day 9, place preference to morphine had 
developed similarly in the Wt (353±16) and 
GDNF+/- mice (357±17, treatment effect: 
P=0.0041�� treatment X genotype interaction: 
P=0.9957, two-way ANOVA). On day 15, 7 
days after the last conditioning session, place 
preference was seen only in the Wt mice (P= 
0.0117�� paired t-test, n=10-20). 
The effects of morphine 10 mg/kg 
on CPP are summarized in Table 5.6. n 
this experiment the duration of morphine-
induced place preference in the Wt and 
GDNF+/- mice was studied by conditioning 
the mice with morphine 10 mg/kg on four 
days and measuring the postconditioning 
times one day, two weeks, three weeks and 
five weeks after the conditioning period. 
The preconditioning times (s±SEM) before 
morphine treatment were similar in the 
Wt and GDNF+/- mice (Wt: 255±23�� 
GDNF+/-: 272±18). Morphine-induced 
place preference developed similarly in both 
genotypes, as on day 8 the time spent in the 
drug-paired side was significantly increased 
both in the Wt mice (P=0.0176, paired t-
test) and in the GDNF+/- mice (P=0.00315, 
paired t-test). However, 2 weeks (day 22) 
and 3 weeks (day 29) after the conditioning, 
retention of the place preference was seen 
only in the Wt mice (P=0.0357�� P=0.0123, 
paired t-test), whereas in the GDNF+/- mice 
the time spent in the drug-paired side had 
Morphine 5 mg/kg Wt GDNF+/-
Day 6 - -
Day 9 + +
Day15 + -
Morphine 10 mg/kg
Day 8 + +
Day 22 + -
Day 29 + -
Day 44 - -
Table 5.6. The effects of morphine 5 and 
10 mg/kg on CPP, - indicates that there was 
no place preference, + indicates that there 
was place preference. Days refer to the 
length of the experiment so that day 1 is 
the first habituation day (see table 4.1). 
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returned to the preconditioning level. Five 
weeks after conditioning (day 44) place 
preference was not seen in the mice of either 
genotype. 
5.10. The effects of codon 919 mutation 
in murine RET (to encode threonine 
rather than methionine) on cerebral tissue 
dopamine, noradrenaline and serotonin 
(IV)
As summarized in Table 5.7, dopamine, 
DOPAC and HVA were significantly 
increased in both the dorsal striatum 
(genotype effect for dopamine, DOPAC 
and HVA: P<0.0001, one-way ANOVA) 
and in the ventral striatum (genotype effect 
for dopamine and DOPAC: P < 0.0001, for 
HVA: P<0.0032 one-way ANOVA) of the 
MEN2B/+ and MEN2B/MEN2B mice as 
compared with their wild-type littermates. n 
the dorsal striatum, dopamine concentrations 
were increased in the MEN2B/+ mice by 
54% and in the MEN2B/MEN2B mice 
by 94% as compared with the Wt mice. 
DOPAC concentrations were increased in 
the MEN2B/+ mice by 102% and in the 
MEN2B/MEN2B mice by 185%. HVA 
concentrations were significantly increased 
by 72% in the MEN2B/+ mice and by 137% 
in the MEN2B/MEN2B mice. n the dorsal 
striatum of the MEN2B/MEN2B mice 
dopamine, DOPAC and HVA concentrations 
were significantly higher than those in the 
MEN2B/+ mice (P<0.01, P<0.01, P<0.05, 
respectively, Tukey/Kramer). n the ventral 
striatum, dopamine concentrations were 
about 60%, DOPAC concentrations about 
120-130% and HVA concentrations about 
80% higher in the MEN2B/+ and MEN2B/
MEN2B than those in the Wt mice. Also, it is 
to be noticed that in contrast to dorsostriatal 
tissues, there were no differences in the 
ventrostriatal dopamine, DOPAC or HVA 
concentrations between the MEN2B/+ and 
the MEN2B/MEN2B mice. 
As summarized in Table 5.8, only 
dopamine concentrations and neither 
noradrenaline nor serotonin concentrations 
were increased in the target areas of 
their neuronal pathways in the MEN2B 
mice. Cortical dopamine was increased 
by about 70% in the MEN2B/+ and 
MEN2B/MEN2B as compared with the 
Wt mice. Cortical DOPAC and HVA 
concentrations were also significantly higher 
MEN2B/+ MEN2B/MEN2B
Dorsal striatum
Dopamine
DOPAC 
HVA
↑     
↑↑↑
↑↑   
**
**
**
↑↑      
↑↑↑↑ 
↑↑↑
** °°
** °°
** °°
Ventral striatum
Dopamine
DOPAC 
HVA
↑     
↑↑↑ 
↑↑ 
**
**
*
 
↑      
↑↑↑  
↑↑    
**
**
**
Table 5.7. Dopamine, DOPAC and HVA concentrations in the post mortem dorso- and 
ventrostriatal tissues in the MEN2B mice. ↑ indicates 50-70 % increase, ↑↑ indicates 70-100% 
increase, ↑↑↑ indicates 100-140% increase ↑↑↑↑ indicates 180-190% increase, * indicates 
P<0.05, ** P<0.01 as compared with the Wt mice, °° indicates P<0.01 as compared with the 
MEN2B/+ mice
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in the MEN2B/+ mice (respectively by 61% 
and 58%) and MEN2B/MEN2B mice 
(respectively by 116% and 89%) than in the 
Wt mice. n the hypothalamus, dopamine, 
DOPAC and HVA concentrations were 
significantly elevated only in the MEN2B/
MEN2B mice (respectively by 32%, 73% 
and 92%) as compared with the Wt mice. 
n the lower brain stem, the concentrations 
of dopamine and its metabolites were small 
and similar in mice of the three genotypes. 
The concentrations of serotonin were 
similar within the three genotypes in all 
brain regions studied. The concentrations 
of noradrenaline did not differ between the 
mice of the three genotypes except in the 
lower brainstem, where the concentration 
was increased by 27% in the MEN2B/
MEN2B mice as compared with the Wt 
mice. 
5.11. Extracellular dopamine, DOPAC 
and HVA concentrations in the dorsal 
striatum of MEN2B/MEN2B mice and in 
their wild-type littermates (unpublished)
As summarized in Table 5.9, extracellular 
dopamine concentrations were similar in 
the Wt and MEN2B/MEN2B mice in the 
dorsal striatum. However, the extracellular 
DOPAC and HVA concentrations were 
increased significantly by 97% and by 62%, 
respectively in the mutant mice (DOPAC: 
P=0.005, HVA: P=0.021, Student’s t-test).
 
5.12. Spontaneous and 24-h locomotor 
activity in knock-in MEN2B mice and in 
their wild-type littermates (IV)
Spontaneous activity in nonhabituated Wt 
and in MEN2B/+ and MEN2B/MEN2B 
mice declined during the 60 min recording 
period. Both the MEN2B/+ and MEN2B/
MEN2B mice moved less than the Wt mice 
(genotype effect: P= 0.0038, repeated measures 
ANOVA) and there were no differences 
between the heterozygous and homozygous 
mice. When the mice were habituated there 
were no differences in 24-h locomotor activity 
between the mice of the three genotypes. 
5.13. The effects of acute cocaine on 
locomotor activity in knock-in MEN2B 
mice and in their wild-type littermates 
(IV)
Table 5.10 summarizes the effects of cocaine 
on locomotor activity in MEN2B mice and 
MEN2B/+ MEN2B/
MEN2B
Cortex
Noradrenaline
Serotonin
Dopamine
↔
↔
↑↑ **
↔
↔
↑↑ **
Hippocampus
Noradrenaline
Serotonin
Dopamine
↔
↔
nd
↔
↔
nd
Hypothalamus
Noradrenaline
Serotonin
Dopamine
↔
↔
↔
↔
↔
↑ *
Lower brain stem
Noradrenaline
Serotonin
Dopamine
↔
↔
↔
↑ ** °
↔
↑
Table 5.8. Dopamine, noradrenaline and 
serotonin concentrations in the post mortem 
cerebral tissues in the MEN2B mice. ↔ 
indicates that the difference compared to 
the Wt mice is less than 20%, ↑ indicates 
20-40 % increase, ↑↑ indicates 50-70% 
increase, ↑↑↑ indicates 80% increase or 
more, nd indicates not detected, * indicates 
P<0.05, ** P<0.01 as compared with the 
Wt mice, ° indicates P<0.05 as compared 
with the MEN2B/+ mice
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MEN2B/+ MEN2B/
MEN2B
Cortex
Noradrenaline
Serotonin
Dopamine
↔
↔
↑↑ **
↔
↔
↑↑ **
Hippocampus
Noradrenaline
Serotonin
Dopamine
↔
↔
nd
↔
↔
nd
Hypothalamus
Noradrenaline
Serotonin
Dopamine
↔
↔
↔
↔
↔
↑ *
Lower brain stem
Noradrenaline
Serotonin
Dopamine
↔
↔
↔
↑ ** °
↔
↑
Table 5.8. Dopamine, noradrenaline and 
serotonin concentrations in the post mortem 
cerebral tissues in the MEN2B mice. ↔ 
indicates that the difference compared to 
the Wt mice is less than 20%, ↑ indicates 
20-40 % increase, ↑↑ indicates 50-70% 
increase, ↑↑↑ indicates 80% increase or 
more, nd indicates not detected, * indicates 
P<0.05, ** P<0.01 as compared with the 
Wt mice, ° indicates P<0.05 as compared 
with the MEN2B/+ mice
in their wild-type littermates. Locomotor 
activity of saline-treated MEN2B mice and 
their wild-type littermates did not differ 
significantly. Cocaine (5, 10 or 20 mg/kg) 
significantly and dose-dependently increased 
locomotor activity in mice of all three 
genotypes. Two-way ANOVA showed that 
the effects of cocaine differed between the 
Wt and MEN2B mice (genotype x treatment 
interaction, P= 0.0055). The effect of cocaine 
5 mg/kg was similar in all genotypes (two-
way ANOVA, genotype effect, P=0.9811). 
Cocaine 10 and 20 mg/kg increased 
locomotor activity significantly more in the 
MEN2B/+ and MEN2B/MEN2B mice 
than in the Wt mice (genotype effect for 10 
mg/kg: P =0.0024 and for 20 mg/kg: P = 
0.0033, genotype x treatment interaction 
for 10 mg/kg: P = 0.0005 and for 20 mg/kg: 
P = 0.0017, two-way ANOVA). n addition, 
cocaine 20 mg/kg increased locomotor 
activity in MEN2B/MEN2B mice more 
than in correspondingly treated Wt mice 
(P<0.01, Tukey/Kramer post hoc test). 
5.14. Effects of repeated cocaine on 
locomotor activity in knock-in MEN2B 
mice and in their wild-type littermates 
(unpublished)
The locomotion-increasing effects of daily 
cocaine doses of 5 mg/kg were similarly 
enhanced on days 2-5 in all genotypes 
(Figure 5.2, ANOVA for repeated measures, 
day effect on days 2-5: P=0.002, n=11-22). 
Thus, the effect of cocaine on locomotion 
was 75-110% higher on day five than on day 
two in all genotypes. 
The effects of daily injections of cocaine 
10 mg/kg were also increased on days 2-5 
in all genotypes (Figure 5.2, lower panel, 
ANOVA for repeated measures, day effect on 
days 2-5: P<0.001, n=7-13). The first dose 
of cocaine 10 mg/kg increased locomotor 
activity in MEN2B/MEN2B mice more than 
in the Wt mice, as the distance travelled by the 
homozygous mutants was 160% higher than 
that of Wt mice (P=0.0298, Student’s t-test). 
Table 5.9. The steady-state extracellular dopamine, DOPAC and HVA concentrations from 
dorsal striatum in the Wt and MEN2B/MEN2B mice, n=6-7, * indicates P<0.05, ** P<0.01 as 
compared with the Wt mice.
 
Table 5.10. The effects of acute cocaine 5, 10 and 20 mg/kg on distance travelled during 
30 min. ↔ indicates that the distance travelled as compared with the corresponding saline 
treatment is increased less than 100%, ↑ indicates that the increase is 100-200%, ↑↑ indicates 
that the increase is 200-350%, ↑↑↑ indicates that the increase is 350-500%, ↑↑↑↑ indicates 
that the increase is 500-850%, * indicates statistically significant difference as compared with 
corresponding saline treatment, ° indicates statistically significant difference as compared with 
corresponding Wt mice.
Dopamine nM DOPAC µM HVA µM
Wt 1.73±0.42 0.31±0.05 0.43±0.05
MEN2B/MEN2B 1.47±0.28 0.61±0.07 ** 0.68±0.07*
Genotype Cocaine 5 mg/kg Cocaine 10 mg/kg Cocaine 20 mg/kg
Wt ↔ ↔ ↑↑↑ **
MEN2B/+ ↔ ↑ * ↑↑↑↑ **
MEN2B/MEN2B ↑ ↑↑ * ↑↑↑↑ ** °°
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When the distances travelled were compared 
between the fourth and the first dose of 
cocaine, there are clear differences between 
the genotypes. n the Wt mice, the increase 
was about 220%, in the MEN2B/+ 90% and 
in the MEN2B/MEN2B mice only 58%. 
However, it is to be noticed that distances 
travelled after the fourth dose of cocaine 10 
mg/kg were similar in all genotypes. 
5.15. TH and DAT protein and mRNA 
expression in the striatum and in the SN/
VTA area (IV)
TH protein levels were clearly increased both 
in the striatum and in the SN/VTA region of 
MEN2B mutant mice as compared with Wt 
mice. Optical density measurements in TH-
immunostained sections showed that the 
MEN2B mutation had a dose-dependent 
effect on striatal TH levels. Optical density 
from immunostained brain sections was 55% 
greater in the MEN2B/+ and 75% greater 
in the MEN2B/MEN2B mice than in the 
Wt mice. This effect was confirmed by the 
Western blotting analysis. n the SN/VTA 
region, TH protein was found to be elevated 
by 60% in the MEN2B/+ and by 180% in 
the MEN2B/MEN2B mice, and also the 
TH mRNA expression was increased by 
about 60% in the MEN2B/MEN2B mice 
as compared with the Wt mice. 
DAT protein levels were increased 
in the striatum in MEN2B mice. Optical 
density measurement revealed about 50% 
increase of DAT in both MEN2B/+ and 
MEN2B/MEN2B mice as compared with 
Wt mice. This effect was confirmed by 
western blotting analysis. n the SN/VTA 
area DAT mRNA expression was found 
to be slightly (30%) but not significantly 
higher in the MEN2B/MEN2B mice than 
in the Wt mice. 
5.16. TH-positive neurons in substantia 
nigra pars compacta and ventral tegmental 
area (IV)
The number of TH-immunostained cells 
in the SNpc was found to be increased 
by 26% in the MEN2B/MEN2B mice as 
compared with the Wt mice (Wt: 354±34, 
MEN2B/+: 387±31, MEN2B/MEN2B: 
448±18, P=0.0246, Student’s t-test). No 
differences were found in the number of TH-
immunostained cells in the VTA between 
the genotypes (Wt: 1161±88, MEN2B/+: 
1131±50, MEN2B/MEN2B: 1207±121.
Figure 5.2. The effects of daily cocaine 
injections on distance travelled (cm) in 
the Wt, MEN2B/+ and MEN2B/MEN2B 
mice. The mice were given saline injections 
on the first day and thereafter daily cocaine 
5 mg/kg i.p. (upper panel) or 10 mg/kg i.p. 
(lower panel). 
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6. DISCUSSION
6.1. Striatal dopaminergic system in mice 
with lowered GDNF concentrations
One of the most unexpected findings in the 
present experiments was that extracellular 
dopamine concentrations were increased 
in both striatal brain regions studied in 
the heterozygous GDNF+/- mice. The 
extracellular dopamine concentration 
increase in GDNF+/- mice, was not 
accompanied by an increase in metabolite 
concentrations, which was expected 
as metabolites have different diffusion 
properties from those of dopamine, and also 
as extracellular metabolite concentrations 
are higher. There was a clear increase in the 
number of FosB/∆FosB and c-Fos positive 
nuclei in the striatal brain regions of these 
mice. Also Messer et al. (2000) reported that 
the accumbal levels of ∆FosB are increased in 
the GDNF+/- mice. The increased number 
of FosB/∆FosB and c-Fos immunostained 
nuclei in the mesolimbic and nigrostriatal 
projection areas of GDNF+/- mice could be 
linked to the elevated extracellular dopamine 
concentrations, as amphetamine or cocaine-
induced increases in ∆FosB and c-Fos levels 
can be blocked by D1-receptor antagonist 
(Berretta et al., 1992�� Nye et al., 1995). 
However, c-Fos and FosB levels are increased 
by a variety of drugs administered acutely and 
by stress (Harlan and Garcia, 1998), whereas 
∆FosB accumulates in striatal brain regions 
during chronic administration of drugs of 
abuse (Nestler et al., 2001). Thus, increased 
FosB/∆FosB levels in the dopaminergic 
projection areas of the GDNF+/- mice 
suggest sustained postsynaptic activation.
Previous studies involving the role of 
endogenous GDNF have shown that there 
are no major changes in the dopaminergic 
systems in homozygous GDNF knockout 
mouse embryos or in heterozygous GDNF+/- 
knockout mice. n mouse embryos lacking 
GDNF there are no differences in the 
number or density of dopaminergic cells in 
the SNpc or in the striatal dopaminergic 
innervation as compared with normal mouse 
embryos (Moore et al., 1996�� Pichel et al., 
1996�� Sanchez et al., 1996). n line with 
previous experiments (Gerlai et al., 2001), 
in the present studies it was found that 
the basal tissue concentrations of striatal 
dopamine and its metabolites are similar 
in the GDNF+/- and in the Wt mice. 
However, it has been shown that GDNF has 
an important role in postnatal development 
of the brain dopaminergic systems. When 
foetal neural tissues lacking GDNF are 
transplanted into the adult mouse brain, 
the number of dopaminergic neurons in the 
ventral midbrain is reduced (Granholm et al., 
2000). n SN of Parkinson’s disease patients, 
decreased levels of GDNF have been found 
(Chauhan et al., 2001). Neurodegeneration 
in Parkinson’s disease is thought to be 
caused by oxidative stress, mitochondrial 
dysfunction, excitotoxicity, inflammation 
and by alterations in neurotrophic factor 
synthesis. As dopamine undergoes oxidative 
metabolism and can generate cytotoxic free 
radicals, increased extracellular dopamine 
levels can be harmful for dopaminergic 
neurons in the long run. ndeed, very recently 
it has been reported that the number of 
dopaminergic neurons originating from the 
SNpc is decreased more in aged GDNF+/- 
mice than in aged Wt mice, starting from the 
age of 12 months (Boger et al., 2006). 
There are several mechanisms that may 
cause the increased extracellular dopamine 
concentrations in the GDNF+/- mice. 
Firstly, as GDNF has been shown to enhance 
outgrowth of dopaminergic neurons and to 
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increase synapse formation (Bourque and 
Trudeau, 2000�� Granholm et al., 2000), 
it is possible that synapse formation of the 
dopaminergic neurons in the GDNF+/- 
mice differ from those of the Wt mice, 
and neurons increase dopamine output to 
maintain normal functioning. Secondly, 
as exogenously administered GDNF has 
been shown to increase stimulus evoked 
dopamine output (Feng et al., 1999�� Hebert 
et al., 1996�� Lin et al., 1993�� Xu and Dluzen, 
2000), which could be related to its ability 
to increase activity of TH (Salvatore et al., 
2004) and to its ability to inhibit transient 
A-type K+-channels (Yang et al., 2001), the 
reduced GDNF levels might affect dopamine 
output through potassium channels. Another 
explanation for increased extracellular 
dopamine concentrations is that there may 
be direct alterations of the dopaminergic 
neurons. Most of the synaptically released 
dopamine is taken up by the DAT and thus, 
one possibility is that the amount or function 
of DAT is altered in the GDNF+/- mice. 
However, it is unlikely that the amount of 
DAT would be altered, as in the present 
experiments, acute administration of cocaine 
stimulated locomotor activity similarly in 
the GDNF+/- and Wt mice, and cocaine-
induced percentage elevations of dopamine 
output in the nucleus accumbens and 
basal motor activities were also similar. n 
addition, our preliminary results from DAT 
immunostained striatal samples did not 
show any differences in the optical density 
measurements. Further studies could be 
conducted to measure dopamine kinetics in 
GDNF+/- mice by using in vivo voltammetry. 
There is evidence of an interaction between 
dopamine D2 receptors and GDNF. 
Dopamine D2-receptor knockout mice have 
reduced GDNF levels (Bozzi and Borrelli, 
1999), and on the other hand, there are 
indications that in the GDNF+/- mice 
the D2 mRNA levels are increased in the 
striatum at the age of 12 months (Boger 
et al. 2004). As presynaptic dopamine D2 
autoreceptor function mediates the feedback 
control of dopaminergic activity, it might 
thus be altered in the GDNF+/- mice.
ncreased dopaminergic transmission 
in striatal brain regions of heterozygous 
GDNF+/- mice might be induced by 
compensatory alterations in the mesolimbic 
and nigrostriatal dopaminergic pathways. 
As GDNF/RET-signalling has been 
shown to be important for functioning of 
the dopaminergic systems, the increased 
dopamine release described above might 
be a compensatory mechanism to enhance 
the synthesis of GDNF. t has been 
demonstrated that dopamine regulates 
GDNF synthesis through D1-receptors, 
but only at high concentrations (Bozzi and 
Borrelli, 1999�� Ohta et al., 2003�� Ohta et al., 
2000). However, we found no differences in 
the numbers of D1-receptors between the 
GDNF+/- and the Wt mice in dopamine 
D1-ligand binding experiments in striatal 
membrane preparations with 3H-SCH-
23390 . 
As multiple neuronal systems are known 
to depend on GDNF for development and 
maintenance, it is possible that the neuro-
transmitter systems regulating dopaminergic 
neurons differ between the GDNF+/- and Wt 
mice. GABA, glutamate, and opioid peptides, 
among several other neurotransmitters, 
are known to regulate dopaminergic 
transmission. ndeed, our results show that 
morphine’s effects on dopamine output and 
metabolism differ between the GDNF+/- and 
Wt mice. Morphine is thought to enhance 
dopamine output by activating µ-opioid 
receptors on GABAergic interneurons in the 
VTA and in the SN. The activation of µ-
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opioid receptors reduces the inhibitory effect 
of GABA, which leads to enhanced release of 
dopamine (Johnson and North, 1992�� Lacey 
et al., 1989). n the present experiments, 
acute morphine at doses of 5 and 10 mg/kg 
increased accumbal dopamine output dose-
dependently in the Wt mice, but in the 
GDNF+/- mice morphine 5 mg/kg enhanced 
the accumbal dopamine output robustly to a 
greater extent more than a dose of 10 mg/kg. 
Also, similar differences were found between 
the genotypes in the effects of morphine on 
accumbal extracellular DOPAC output. Also, 
the morphine-induced elevations in striatal 
DOPAC and HVA tissue concentrations were 
dose-dependent in mice of both genotypes, 
but the effect of 30 mg/kg was significantly 
smaller in the GDNF+/- mice than in the Wt 
mice. Moreover, as the GDNF binding co-
receptor GFRα1 has been shown to be located 
both in the dopaminergic and GABAergic 
neurons in the midbrain (Sarabi et al., 2001), 
GDNF is likely to regulate their functions. 
As GABAergic interneurons in the VTA and 
SN play an essential role in the mechanism 
of action of morphine, it is possible that 
the GABAergic regulation of dopaminergic 
neurons is altered in the GDNF+/- mice as 
compared with their wild-type littermates. 
Maisonneuve et al. (2001) has reported 
that in rats, the dose response curve of 
morphine’s effect on dopamine output in the 
nucleus accumbens and caudate/putamen is 
bell-shaped. Morphine increases dopamine 
output up to certain dose, and after maximal 
effects, increasing of the dose reduces the 
dopamine response. Morphine appears to 
have a dual effect on striatal dopamine 
release: an inhibitory effect in the terminal 
regions and a stimulatory effect in the 
somatodendritic regions. Our laboratory 
previously reported that intrastriatal 
administration of µ-opioid receptor agonists 
morphine and DAMGO ([D-Ala2,MePhe4,
glycinol5]enkephalin) decreases extracellular 
striatal dopamine (Piepponen et al., 1999). 
Our results suggest that the bell-shaped dose-
response curve of morphine is shifted to the 
left in the GDNF+/- mice. t is possible that 
morphine’s inhibitory effect on dopamine 
release in the terminal regions becomes 
predominant in the GDNF+/- mice at 
smaller doses than in the Wt mice. 
6.2. Effects of repeated administration of 
cocaine, amphetamine and morphine on 
locomotor activity in the GDNF+/- mice
Psychomotor sensitization is a long-lasting 
plastic phenomenon and it may be involved 
in drug-seeking behaviour and in the 
development of drug addiction (Robinson 
and Berridge, 2003). The locomotor responses 
to repeated cocaine and amphetamine were 
sensitized similarly in the GDNF+/- and Wt 
mice. n contrast to the study of Messer et. al. 
(2000), in the present experiments cocaine 
did not induce more robust behavioural 
sensitization in the GDNF+/- mice than in 
the Wt mice. However, our result is in line 
with a similar observation by Griffin et al. 
(2003).
  
n the morphine experiment, we 
found that tolerance to morphine-induced 
locomotor stimulation developed faster in 
the GDNF+/- than in the Wt mice. Tolerance 
is an important component of the actions of 
opioids. t is thought that development of 
tolerance and drug addiction are caused by 
plastic neuroadaptive changes induced by 
chronic drug administration (Nestler et al., 
2001). As neurotrophic factors are also crucial 
for the plasticity of the CNS, it is likely that 
they may be involved in long-term responses 
to drug exposure. ndeed, our results indicate 
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that endogenous GDNF is involved in the 
development of tolerance to morphine. After 
96 h withdrawal from repeated morphine 
treatment, the effects of morphine at 5 mg/
kg were found to be sensitized only in the 
GDNF+/- mice�� however, increasing the dose 
induced robust and similar sensitization in 
mice of both genotypes. This clearly indicates 
that GDNF+/- mice are more vulnerable to 
morphine-induced psychomotor sensitization 
than their wild-type littermates. 
The transcription factor ∆FosB has 
been linked to psychomotor sensitization 
and drug addiction (Nestler et al., 2001). n 
the present experiments, basal levels of FosB/
∆FosB were increased in the GDNF+/- mice 
as compared with the Wt mice. Thus, the 
increased sensitivity of the GDNF+/- mice 
to psychomotor sensitization to morphine 
5 mg/kg might well be related to increased 
FosB/∆FosB levels in brain areas involved in 
addiction.
6.3. Effects of repeated cocaine and 
morphine on accumbal dopamine output
Another unexpected finding in these studies 
was that, after repeated morphine and 
cocaine treatments, the elevation of basal 
extracellular dopamine concentrations seen 
in drug-naive GDNF+/- mice was restored 
to a similar level as in Wt mice. Repeated 
morphine treatment has been shown to 
cause several neuroadaptations in the 
VTA. Withdrawal from chronic morphine 
treatment retards striatal dopamine 
metabolism (Ahtee and Attila, 1987�� Ahtee 
et al., 1989�� Attila and Ahtee, 1984) and 
decreases the size and calibre of dendrites 
and cell bodies of VTA dopamine neurons 
(Nestler, 1992). Chronic morphine has 
been shown to increase the levels of TH 
in the VTA (Beitner-Johnson and Nestler, 
1991�� Self et al., 1995), an effect that can 
be blocked by exogenous GDNF (Messer 
et al., 2000). n addition, drugs of abuse 
have been shown to have direct effects on 
GDNF-GFRα1/RET signalling in the 
dopaminergic system, as chronic cocaine 
and morphine decrease the amount of 
phosphorylated RET in the VTA (Messer et 
al., 2000) and as chronic cocaine decreases 
the amount of GDNF mRNA in the 
striatum (Green-Sadan et al., 2003). 
Thus, apparently repeated morphine 
treatment modifies the plasticity of the 
dopaminergic system more readily in mice 
with reduced telencephalic GDNF, which 
suggestion is also supported by more rapid 
development of tolerance to the locomotor 
enhancing effects of morphine discussed 
above. 
There is ample evidence for the 
involvement of dopaminergic systems in 
sensitization phenomenon (Ahtee and Attila, 
1987�� Di Chiara, 1995�� Spanagel and Weiss, 
1999). n the present experiments, repeated 
administration of cocaine did not induce 
sensitization of dopamine release in either 
the Wt or the GDNF+/- mice. n accordance 
with the increased psychomotor sensitization 
to morphine 5 mg/kg, this challenge dose 
increased accumbal dopamine output 
slightly more in the GDNF+/- than in the 
Wt mice after repeated treatment. The robust 
and similar psychomotor sensitization seen 
in mice of both genotypes after morphine 
10 mg/kg agrees with the finding that, at 
this challenge dose, morphine enhanced 
accumbal dopamine output similarly in the 
Wt and GDNF+/- mice. n the GDNF+/- 
mice, morphine 10 mg/kg induced a greater 
locomotor response than the 5 mg/kg dose 
although both morphine doses increased the 
accumbal dopamine output similarly. Also, 
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the cocaine-induced dopamine output was 
significantly lower in the GDNF+/- mice 
than in the Wt mice. Furthermore, in the 
GDNF+/- mice, the effect of a challenge 
dose of morphine 5 mg/kg on dopamine 
output after repeated treatment was clearly 
less than that of an acute 5 mg/kg dose. 
Thus, it is likely that also other mechanisms 
besides enhanced accumbal dopamine 
output after repeated treatment are involved 
in the psychomotor sensitization. 
6.4. Effects of morphine on CPP
The CPP is used to assess the rewarding 
properties of drugs. Morphine-induced 
CPP has been shown to persist for a long 
time (Mueller et al., 2002). ncreased 
GDNF concentrations have been shown 
to attenuate reward (Green-Sadan et al., 
2003�� Green-Sadan et al., 2005�� He et al., 
2005�� Messer et al., 2000) and reduced 
GDNF concentrations to augment it 
(Griffin et al., 2006�� Messer et al., 2000). 
As accumbal dopamine plays an important 
role in the drug reward and we found that 
acute morphine 5 mg/kg increases accumbal 
dopamine clearly more in the GDNF+/- 
mice than in the Wt mice, we wanted to 
investigate the development and duration 
of morphine-induced CPP in the GDNF+/- 
mice. We showed that morphine 5 and 10 
mg/kg induced CPP initially similarly in 
the GDNF+/- and Wt mice. However, the 
morphine-induced CPP lasted longer in the 
Wt than in the GDNF+/- mice in both the 
CPP paradigms used. Thus, an augmented 
response of accumbal dopamine to acute 
morphine 5 mg/kg in the GDNF+/- mice 
does not apparently affect the development 
of place conditioning. ndeed, the duration 
of place preference in the GDNF+/- mice 
was relatively short. The shortened duration 
of morphine-induced CPP in the GDNF+/- 
mice might be related to their impaired 
spatial working memory as seen by weakened 
water maze learning performance (Gerlai et 
al., 2001) rather than impaired appetitive 
value of morphine. However, weakened 
spatial memory is difficult to reconcile with 
the initially similar development of place 
preference in the GDNF+/- mice.
6.5. Brain dopaminergic system in mice 
with constitutively active RET
The present experiments show that 
constitutive RET activity, induced by a 
Met919Thr mutation, leads to robust 
increases in brain tissue dopamine 
concentrations in mesolimbic, mesocortical 
and nigrostriatal systems. n addition, the 
mutation seems to be rather specific for the 
dopaminergic system as noradrenaline or 
serotonin concentrations were not altered 
in the MEN2B mice. There may be two 
main reasons for increased dopamine 
concentrations. Firstly, as TH protein levels 
were increased in the striatal brain areas of 
the MEN2B mice, it is likely that increased 
dopamine levels are caused by increased 
synthesis. Secondly, it is likely that some of 
the increase in dopamine concentrations is 
due to the increased cell number, since in 
the SNpc of homozygous MEN2B mice the 
number of TH-positive cells was found to 
be increased by 26%. 
Knockout studies have shown that 
GDNF-RET signalling is not important 
during embryonic development for 
midbrain dopaminergic neurons (Enomoto 
et al., 1998�� Marcos and Pachnis, 1996�� 
Moore et al., 1996�� Pichel et al., 1996�� 
Sanchez et al., 1996). However, it has been 
shown that the number of dopaminergic 
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neurons is regulated during early postnatal 
development. This development has been 
shown to be dependent upon GDNF 
(Kholodilov et al., 2004�� Oo and Burke, 
1997�� Oo et al., 2003). Our finding of 
increased numbers of TH-positive neurons 
in the MEN2B mice is thus more likely 
to be due to neurotrophic support during 
postnatal apoptotic phases. However, it is 
also possible but less likely that increased 
TH-positive cell numbers in the SNpc 
are due to increased RET activity during 
embryonic development, possibly related 
to more neurons acquiring a dopaminergic 
phenotype. 
The most prominent elevations of 
tissue dopamine levels were found in the 
dorsal striatum of the homozygous MEN2B 
mice, where the effect on dopamine 
concentrations was mutation-dependent. 
However, in the ventral striatum and in the 
cortex, dopamine was similarly elevated in 
the heterozygous and homozygous mutants, 
suggesting that in these brain areas dopamine 
concentrations are maximally elevated by 
even a lower RET activity. The extracellular 
dopamine concentrations in the dorsal 
striatum did not differ between the Wt and 
MEN2B/MEN2B mice, indicating that 
dopamine in the MEN2B mice is increased 
only intracellularly. The normal extracellular 
dopamine concentration in the MEN2B/
MEN2B mice is in accord with the finding 
that their striatal DAT level is increased, 
and thus, there is more rapid uptake for 
released dopamine. The normal extracellular 
dopamine concentration in MEN2B/
MEN2B mice is also in agreement with the 
finding that 24-h locomotor activities of 
MEN2B mice did not differ from those of 
the Wt mice. However, reason for the reduced 
exploratory activity in the mice of both 
MEN2B genotypes remains unclear. t might 
be due to effects of RET on motoneurons or 
sympathetic ganglia, but it is also temping 
to suggest that presynaptic D2 receptors 
function is altered in these mice. Activation 
of presynaptic dopamine D2 receptors is 
known to reduce locomotion, and these 
autoreceptors are known to be activated by 
a smaller dopamine concentration than the 
postsynaptic receptors (Carlsson, 1977). 
As the tissue concentrations of 
dopamine metabolites were increased in 
the MEN2B mice, it is likely that increased 
tissue dopamine is not caused by decreased 
metabolism in the MEN2B mice. DOPAC 
and HVA concentrations were also found 
to be increased extracellularly, which 
indicates that additional intracellular 
dopamine, which is not stored into vesicles, 
is metabolized. DOPAC is mainly an 
intracellularly produced metabolite (Roffler-
Tarlov et al., 1971) and HVA is formed 
outside of the dopaminergic neuron (Wood 
and Altar, 1988). 
The finding that TH is up-regulated 
due to constitutive RET activity is rather 
surprising. Although, GDNF has been 
shown to increase the expression and stability 
of TH mRNA (Xiao et al., 2002) and to 
increase dopamine levels and turnover in 
the striatum and SN (Hudson et al., 1995�� 
Martin et al., 1996), chronic and even acute 
GDNF treatments have been shown to down 
regulate TH expression (Georgievska et al., 
2004�� Salvatore et al., 2004). The GDNF-
induced TH down regulation is thought to 
be a compensatory alteration maintaining 
the functional stability of the dopaminergic 
system. However, the present findings 
indicate that in the MEN2B mice, increased 
tissue dopamine is evidently compensated 
by other mechanisms, such as increased 
DAT levels. 
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6.6. Effects of cocaine in the MEN2B 
mice
The finding that the MEN2B mice are more 
sensitive to the stimulatory effect of acute 
cocaine is in line with increased striatal 
dopamine concentrations and up-regulation 
of DAT in these mice. As dopaminergic 
nerve endings of MEN2B mice are loaded 
with dopamine, it is likely that cocaine 
increases dopamine output more in these 
mice and induces greater locomotor activity 
than in the Wt mice. 
When cocaine was given repeatedly 
there were no differences in the effects of 
cocaine at 5 mg/kg between the genotypes. 
However, the effects of cocaine 10 mg/kg 
differed, so that in the MEN2B/MEN2B 
the relative increase of the stimulatory 
effect by the daily cocaine injections was 
clearly smaller than that in the Wt mice. 
Nevertheless, this experiment does not 
confirm the hypothesis that GDNF/RET 
signalling reduces drug reward or protects 
against drug addiction. 
6.7. Role of neurotrophic factors in the 
development of drug addiction
As reviewed in section 2.4.5, the present 
hypothesis on the role of GDNF in the 
effects of abused drugs is that increased 
GDNF levels in the mesolimbic system 
attenuate and decreased levels of GDNF 
augment molecular or behavioural changes 
induced by abused drugs. This hypothesis 
is also supported by the present findings 
that in GDNF+/- mice the development 
of tolerance to morphine’s locomotor 
enhancing effect is faster, and that in 
mice with reduced GDNF levels there is 
increased sensitivity to morphine-induced 
psychomotor sensitization. Furthermore, 
morphine robustly increased dopamine 
output when given acutely as a small 
dose. However, in contrast to the above 
hypothesis, we found that the rewarding 
effects of morphine are initially similar in 
the GDNF+/- mice and in their wild-type 
littermates. n addition, although increased 
RET activation increases the stimulatory 
effects of cocaine on locomotion acutely, the 
locomotor sensitization to cocaine is smaller 
in the mice with constitutive RET activity. 
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7. CONCLUSIONS
- The present findings stress the importance of endogenous GDNF in the regulation of brain 
dopaminergic systems. An important finding in the present experiments was that extracellular 
dopamine concentration is increased in both mesolimbic and nigrostriatal brain areas of the 
heterozygous GDNF mice. This finding is further supported by the increase in the number 
of FosB/∆FosB and c-Fos positive nuclei in the postsynaptic neurons in striatal brain areas 
of these mice. Thus, the results indicate that neuronal activity in dopaminergic brain areas 
of heterozygous GDNF+/- mice, with reduced striatal concentrations of GDNF protein, is 
increased. 
- The present findings show that accumbal dopamine output in the heterozygous GDNF+/- 
mice is more sensitive to a small dose of morphine than in their wild-type littermates, and the 
apparent bell-shaped dose-response curve of morphine is shifted to the left. Another important 
finding in the present experiments was that after repeated morphine and cocaine treatments the 
elevation of basal extracellular dopamine concentrations seen in drug-naive GDNF+/- mice was 
restored to a similar level as in the Wt mice. Although, development of psychomotor sensitization 
to cocaine, amphetamine and morphine at 10 mg/kg was similar between GDNF+/- and Wt 
mice, these findings suggest that reduced GDNF levels increase sensitivity to psychomotor 
sensitization to a 5 mg/kg morphine dose, and that GDNF is involved in the development of 
tolerance to locomotor enhancing effects of morphine. Thus, our findings suggest that reduced 
brain GDNF levels alter the response of dopaminergic systems to morphine. The initial 
rewarding effects of morphine as measured by CPP appear to be similar in the GDNF+/- and 
the wild-type mice but the duration of preference lasts longer in the wild-type mice, suggesting 
that endogenous GDNF has a crucial role also in drug-associated motivational memory.
-  The present results show that sustained, increased activity of RET dramatically increases 
telencephalic concentrations of dopamine, mainly by increasing dopamine synthesis. 
Furthermore, these results strongly argue for the role of RET tyrosine kinase as a signalling 
receptor of GDNF in the dopaminergic system. n addition, the increased number of TH-
positive cells in the SNpc of homozygous MEN2B mice clearly shows in vivo that RET 
signalling is involved in the regulation of the number nigrostriatal neurons. However, neither 
the extracellular dopamine concentration nor the 24-h locomotor activity was elevated in 
the MEN2B mice, indicating the dopaminergic systems’ ability to compensate in order to 
maintain normal functioning. 
- Taken together, the present experiments emphasize the role of GDNF/RET-signalling in the 
regulation of brain dopaminergic systems and drug addiction. 
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